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Atherosclerosis is the leading cause of mortality in many countries. It is an 
inflammatory disease of large and medium sized arteries characterized by 
hyperlipidemia. Dendritic cells (DCs) are one of the key players of the 
inflammatory brigade in atherosclerotic plaques and are known to accumulate 
in atherosclerosis. Past studies in atherosclerosis rely on classical markers 
such as CD11c and MHC class II to characterize DCs. However, recent 
identification of non-lymphoid tissue DC subsets based on additional markers 
such as CD11b and CD103 was introduced. Consequently, the need to 
distinguish DC populations in the atherosclerotic plaques arises. Based on the 
new classification, we managed to identify two different DC subsets, CD11b+ 
and CD103+ in the aorta at steady state, which localized at sites of predilection 
for atherosclerosis. Using the apoE-/- mouse model of atherosclerosis, we 
showed that both CD11b+ and CD103+ DCs expanded during disease, with 
CD11b+ DCs being the dominant population. Expansion of CD11b+ DCs was 
abrogated when we treated apoE-/- mice with a cholesterol-lowering drug, 
Ezetimibe. Since monocytosis is prominent in apoE-/- mice and was also 
abolished in Ezetimibe-treated apoE-/- mice, we hypothesized that monocytes 
may be the precursors of CD11b+ DCs. Supporting this hypothesis, adoptively 
transferred monocytes differentiated into CD11b+ DCs in the aortas of apoE-/- 
mice. Moreover, employing the use of a monocyte-derived cell marker CD64, 
we showed that the proportion of CD11b+ DCs expressing CD64 in apoE-/- 
mice was increased as compared to wild-type (WT) controls. For DC 
 xii 
 
differentiation to occur, growth factors are essential to the process. When we 
investigated which growth factors were present in atherosclerotic plaques, we 
discovered that only granulocyte-macrophage colony-stimulating factor (GM-
CSF) was highly expressed in atherosclerotic aorta compared to normal aorta. 
Interestingly, this over-expression of GM-CSF was only detected in 
atherosclerotic plaques and not found in the circulation and aorta-associated 
draining lymph node. Subsequently, we showed that neutralizing GM-CSF 
partially diminished monocytosis and CD11b+ DC accumulation, 
demonstrating that GM-CSF is required for the expansion of CD11b+ DCs. We 
have also explored other possible mechanisms such as proliferation, expansion 
of bone marrow progenitors and extramedullary hematopoiesis and discounted 
their role in CD11b+ DC accumulation.  
Next, we initiated a study to examine the function of CD11b+ DCs. CD11b+ 
DCs produce pro-inflammatory factors, tumor necrosis factor alpha (TNF-α) 
and inducible nitric oxide synthase (iNOS) which are known to be pathogenic 
in atherosclerosis. As one of the by-products of iNOS activity is peroxynitrite 
which results in protein nitration and alteration of protein function, we found 
that CD11b+ DCs localized with sites of nitration in atherosclerotic plaques. 
Likely, CD11b+ DCs have a pro-inflammatory role in atherosclerosis. 
According to our findings, we suggest that by targeting monocytosis and GM-
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Chapter 1 – Introduction 
1.1 Function and composition of aorta 
 
Aorta is the largest artery in the body and functions to distribute oxygenated 
blood throughout the body. The most important role of the aorta is its non-
linear elasticity in response to pulsatile flow (Grotenhuis and de Roos, 2011). 
It is composed of three layers: intima, media and adventitia (Figure 1.1).  The 
intima layer is lined with endothelial cells responsive to blood flow whereas 
the media layer consists of smooth muscle cells interspersed between elastic 
fibers. The outermost layer which is the adventitia provides further support to 
aorta with its connective tissue network.   
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Figure 1.1 Diagram of an arterial wall. 
Artery wall of aorta is made up of 3 layers: intima, media and adventitia. The innermost layer which is the intima is lined with endothelial cells. 
Media lies between the intima and adventitia and is composed of smooth muscle cells and elastic fibers, providing elasticity to the aorta. The 
adventitia made up of connective tissue and collagen extends additional support and structure to the aorta. Image on the right adapted from 
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1.2 Anatomy of the aorta and its role in the development of 
atherosclerosis – the “response to injury” hypothesis 
 
The aorta is a highly-branched and curved tubular structure with bifurcations 
(Berillis, 2013) (Figure 1.2). As a result, the pulsatile flow of blood through 
the aorta generates hemodynamic forces – biomechanical forces such as wall 
shear stress that can alter vessel biology. Notably, disturbed flow patterns are 
found at branching points, curvature and bifurcations of the aorta and seem to 
correlate well with sites of atherosclerosis (Figure 1.3) (VanderLaan et al., 
2004).  
Atherosclerosis is a complex disease of the aorta associated with 
hyperlipidemia and is characterized by intimal thickening. There are numerous 
hypotheses behind the development of atherosclerosis. Regardless, it is 
universally agreed that atherosclerosis is initiated by the activation and 
dysfunction of endothelial cells (Weber et al., 2008). As endothelial cells are 
the one in close contact with blood flow, they are predictably most affected by 
hemodynamic forces. Indeed, their ellipsoidal shape and parallel alignment in 
laminar flow regions (atherosclerosis-resistant regions) were disrupted in 
disturbed flow areas (atherosclerosis-prone regions) (Figure 1.4) (Gimbrone 
and Garcia-Cardena, 2013). This change allows increased permeability of the 
endothelium to lipoproteins. Thus, “the response to injury” model was born 
(Ross, 1999).  
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1.3 The “response to modified lipoprotein” theory in the development 
of atherosclerosis 
 
Another theory behind the development of atherosclerosis is “the response to 
modified lipoprotein” (Steinberg and Witztum, 1990). Hyperlipidemia, a 
condition whereby abnormally high levels of lipids circulate in the blood, is a 
well-known risk factor for atherosclerosis. It has been shown that 
hyperlipidemia can cause a focal loss of endothelial cells with alterations in 
their morphology (Ross and Harker, 1976). In addition, circulating lipids and 
lipoproteins can be modified by an oxidation process in atherosclerotic 
lesions. These modified lipids and lipoproteins in turn induced the expression 
of cell adhesion molecules and monocyte-chemoattractant protein 1 (MCP-1) 
in endothelial cells, resulting in increased migration and adhesion of 
monocytes, encouraging foam cell formation (Stancu et al., 2012).   
 
Chapter 1 - Introduction 
6 
 
    
 
Figure 1.2. Anatomy of aorta.  
The aorta can be divided into five sections: ascending aorta, aortic arch, 
thoracic aorta, descending aorta and abdominal aorta. The ascending aorta is 
the area between the heart and aortic arch. The aortic arch as its name suggests 
is the area of curvature after the ascending aorta. The descending aorta which 
is the region after the arch and all the way to the iliac bifurcation is further 
separated into thoracic and abdominal regions. Thoracic aorta is above the 
diaphragm while abdominal aorta is below the diaphragm. Adapted from 
(Berillis, 2013). 
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Figure 1.3. Wall shear stress correlates with sites of atherosclerotic 
lesions.  
Left: time-averaged wall shear stress in a C57BL/6 mouse adapted from (Huo 
et al., 2008). Right: Predilection sites of atherosclerotic lesions in 
atherosclerotic apoE-/- mice adapted and modified from (Nakashima et al., 
1994).
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Figure 1.4. Morphology of endothelial cells in atherosclerosis-prone and 
atherosclerosis-resistant areas in aorta.  
En face confocal microscopy of endothelium stained with CD31. Adapted 
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1.4 The “immunological hypothesis” in development of atherosclerosis 
 
Infiltration of immune cells into atherosclerotic lesions was observed as early 
as mid 19th century. While Carl von Rokitansky believed that the injury to the 
endothelium resulted in damaged endothelium and inflammation,  Rudolf 
Virchow advocated their primary role in triggering atherosclerosis (Mayerl et 
al., 2006). In fact, activated T lymphocytes could be found in early and late 
atherosclerotic plaques (Hansson et al., 1988; Stratford et al., 1986; Xu et al., 
1990). However, the nature of antigen involved was unknown until 
immunization with heat shock protein (hsp) 65 was found to induce 
atherosclerosis at predisposed sites in normocholesterolemic rabbits (Xu et al., 
1992). Moreover, hsp65-reactive T cells were found in the circulation and 
atherosclerotic lesions of these animals (Xu et al., 1993).   
Heat shock proteins are a group of stress proteins that are constitutively 
expressed or induced by bacterial infections, high temperature, mechanical 
stress, hypoxia etc. Remarkably, expression of hsp60 is up-regulated in 
endothelial cells when exposed to shear stress (Hochleitner et al., 2000) or 
when exposed to cytokines (Xu et al., 1994), reiterating the importance of 
endothelial cell dysfunction in atherogenesis.  
Since hsp 65 and other members of the family have been implicated as 
possible autoantigens in autoimmune diseases such as systemic lupus 
erythematosus (SLE) (Minota et al., 1988) and rheumatoid arthritis (RA) 
(Tsoulfa et al., 1989), likewise it could function as an autoantigen in 
atherosclerosis (Blasi, 2008; Nilsson and Hansson, 2008). In fact, patients with 
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SLE and RA have a higher risk of atherosclerosis (Abou-Raya and Abou-
Raya, 2006; Frostegard, 2002).  
The discovery of mononuclear cell infiltration in normal healthy children at 
sites subjected to hemodynamic stress led to the postulation of a “vascular-
associated lymphoid tissue” (VALT) (Waltner-Romen et al., 1998). 
Analogous to mucosa-associated lymphoid tissue (MALT), VALT is assumed 
to function as a local immune surveillance site for potentially harmful antigens 
(Millonig et al., 2001b; Wick et al., 1997). The consequence of destabilization 
of VALT by autoantigens such as hsp and oxidized low-density lipoprotein 
(oxLDL) is hypothesized to be the initiating event in the development of 
atherosclerosis (Lord and Bobryshev, 2002). At present, atherosclerosis is 
recognized as a chronic inflammatory disease with contributions from both the 
innate and adaptive immunity (Hansson and Libby, 2006).
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1.5 The developmental stages of atherosclerotic lesions 
 
The development of atherosclerosis is a continual process with contributions 
from various immune cells at different stages. Thus, to differentiate the type of 
atherosclerotic lesions and facilitate the identification of cells that contribute 
to the disease progression, atherosclerosis can be classified into Type I to VI 
lesions (Stary et al., 1995; Stary et al., 1994) (Figure 1.5).  
Briefly, Type I lesions are composed of lipid deposits in the intima and 
minimal foam cell formation. Accumulation of lipid-laden foam cells and 
smooth muscle cells constitute Type II lesions. Foam cells are cholesterol 
loaded macrophages displaying a “foamy” appearance and are typically 
present in atherosclerotic lesions. Type III lesions, which are termed 
preatheromas, consist of scattered extracellular lipid pools lying below layers 
of foam cells that disrupt smooth muscle cell organization.  
Formation of a lipid core that is postulated to form from the extracellular lipid 
pools in Type III lesions distinguished Type IV lesions from Type III and 
atherosclerotic lesions from this stage onwards are considered to be advanced. 
Type V lesions are classified as lesions in which prominent new fibrous 
connective tissue is formed and a fibrous cap is developed. When disruption of 
the plaque surface, hematoma or hemorrhage and thrombotic deposits occurs 
in Type IV or Type V lesions, the lesions then become Type VI lesions. 
Chapter 1 - Introduction 
12 
 
Figure 1.5. Stages in the development of atherosclerosis.  
(A) Endothelial-cell dysfunction and activation under 
hyperlipidemia led to increased leukocyte adhesion and 
increased permeability of endothelium (Type I lesion). (B) 
Monocytes are recruited to the intima, accumulate lipids and 
transform into foam cells. Fibroproliferative plaques result 
from the continual mononuclear cell infiltration and smooth 
muscle cell recruitment (Type II and III lesion). (C) 
Apoptosis of foam cells leads to necrotic core formation and 
a fibrous cap of smooth muscle cells forms on top of the 
plaque at this stage (Type IV and V lesion). (D) Thinning of 
fibrous cap in unstable plaques lead to plaque rupture and 
activation of coagulation system and thrombosis (Type VI 
lesion). Adapted and modified from (Weber et al., 2008). 
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1.6 Animal models of atherosclerosis 
 
Much of what we know about atherosclerosis came about with animal models 
of atherosclerosis and there are many available in the field. However, mouse 
models are preferred over the larger animal models mainly due to the ease of 
genetic manipulation and a shorter period for disease development (Getz and 
Reardon, 2012). The two most commonly used mouse model of 
atherosclerosis are: apolipoprotein E-deficient (apoE-/-) and low-density 
lipoprotein receptor-deficient (Ldlr-/-) mice.  
ApoE was first discovered as a lipoprotein constituent of very low density 
lipoprotein (VLDL) in 1973 (Shore and Shore, 1973). It is also part of a 
subclass of high density lipoproteins (HDL) and chylomicrons. Patients with 
type III hyperlipoproteinemia showed an accumulation of apoE-enriched β-
VLDL (Havel and Kane, 1973). Coupled with the observations that apoE 
became a major constituent of cholesterol-enriched lipoproteins that 
accumulated in monkeys fed with cholesterol (Mahley et al., 1976), it was 
clear that apoE plays a major role in cholesterol metabolism. Since apoE 
functions as a ligand for lipoprotein recognition and clearance by lipoprotein 
receptors, apoE-/- mice have a delayed clearance of lipoproteins, resulting in 
severe hypercholesterolemia in these mice. ApoE-/- mice developed 
atherosclerotic lesions spontaneously on normal chow diet but the disease 
progression is accelerated when the mice are fed a high fat, rich cholesterol, 
diet (Nakashima et al., 1994). 
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Ldlr is a surface glycoprotein that regulates plasma cholesterol by mediating 
endocytosis of LDL and is the receptor for apoE. Mutations in this gene 
caused familial hypercholesterolemia in humans with cutaneous xanthomas 
(Hobbs et al., 1990). Ldlr-/- mice were created to recapitulate the 
characteristics of this disease. Ldlr-/- mice only develop atherosclerosis when 
placed on a high fat, rich cholesterol diet and display widespread 
xanthomatosis (Ishibashi et al., 1994).  
Typically, Type I to Type V lesions can be observed in apoE-/-and in Ldlr-/- 
mice, only lesions up to Type IV have been classified (Whitman, 2004).  
However, Type VI lesions have been only reported in the inominate arteries of 
apoE-/- mice (Rosenfeld et al., 2000) and is still a matter of contention (Getz, 
2000). The severity of disease observed in apoE-/- mice compared to Ldlr-/- 
mice is due to a receptor known as LDLR-related protein (LRP). In mice, 
apolipoprotein B48 (apo-B48) in the liver uptake lipoproteins via apoE and is 
dependent on LRP for their clearance from plasma (Veniant et al., 1998).   
The pattern of atherosclerosis development in both mouse models is 
remarkably similar to humans except that mice seldom develop atherosclerosis 
in coronary arteries and do not exhibit unstable atherosclerotic plaque with 
features of thrombosis (Getz and Reardon, 2012; Reddick et al., 1994).
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 1.7 Dendritic cells  
 
Dendritic cells are one of the predominant immune cell types found in 
atherosclerotic plaques (Libby et al., 2013; Shimada, 2009; Weber et al., 2008; 
Woollard, 2013). The first account of dendritic cells (DCs) describing their 
stellate morphology was attributed to Steinman and Cohn (Steinman and 
Cohn, 1973). DCs are the most potent antigen-presenting cells (APCs) in the 
immune system and have an unparalleled ability in priming naïve T cells (Liu, 
2001; Steinman, 1991). Their functions in the immune system can be 
summarized as follows: 1) as sentinels, they can sample the environment to 
uptake, process and present antigens; 2) migrate to lymph nodes where they 
can activate the adaptive immune response; 3) as cross-presenting APCs, they 
regulate CD8+ T cell tolerance and initiate anti-viral and anti-tumor immunity 
(Brode and Macary, 2004; Hart, 1997; Joffre et al., 2012; Shortman and Liu, 
2002).  
 
1.7.1 Ontogeny of DCs  
 
Since DCs have a limited lifespan, they are thought to be replenished by 
circulating precursors in the blood (Liu et al., 2007) or local tissue-derived 
precursors (Naik et al., 2006). Recent literature has revealed that progenitors 
for DCs exist in the bone marrow (Auffray et al., 2009a; del Rio et al., 2008; 
Fogg et al., 2006; Liu et al., 2009; Naik et al., 2007; Onai et al., 2007) (Figure 
1.6).  
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In the bone marrow, macrophage and DC progenitor (MDP) is the first step 
towards commitment to DC lineage. MDP is identified by CX3CR1, c-kit, 
Flt3, CD115 and does not express markers for lineage-committed cells. They 
are able to differentiate into monocytes, macrophages and steady state DCs in 
vivo, having lost the potential for giving rise to granuloctyes, erythrocytes and 
megakaryocytes (Fogg et al., 2006; Liu et al., 2009). 
Common DC progenitor (CDP), defined similarly as MDP but expressing a 
lower expression of c-kit was discovered later as a descendent of MDP. CDP 
is only able to generate plasmacytoid DCs (pDCs) and DCs in vivo (Naik et 
al., 2007; Onai et al., 2007). An intermediate population known as pre-DC is 
produced from CDP. Pre-DCs do not possess lineage markers and start 
expressing CD11c, distinguishing them from MDP and CDP. They can be 
found in the bone marrow, blood, spleen and lymph nodes (Liu et al., 2009) 
and are able to give rise to non-lymphoid tissue DCs in the liver and kidney 
(Ginhoux et al., 2009).  





Figure 1.6. Dendritic cell lineage.  
The two main DC precursors in the bone marrow are MDP and CDP. MDP 
gives rise to monocytes and CDP. Monocytes can become either macrophages 
or DCs. CDP subsequently becomes pre-DCs that exits from the bone marrow 
into circulating blood and into tissues to differentiate into lymphoid and non-
lymphoid tissue DCs. HSC, hematopoietic stem cell; CMP, common myeloid 
progenitor; GMP, granulocyte and macrophage progenitor; CDP, common DC 
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1.7.2 Heterogeneity of DCs in mice 
 
With a multitude of functions to play, it is expected that DCs are made up of 
different subpopulations diverse in functions and origin and differ in their 
migratory abilities. They can be categorized into two groups: conventional and 
non-conventional DCs.  
Conventional DCs (cDCs) are further subdivided into lymphoid-tissue-
resident DCs and migratory DCs (Shortman and Naik, 2007). In mice, 
lymphoid-tissue-resident DCs can be separated into CD8α+ (CD205hi CD11b-) 
and CD8α- cDCs (CD205- CD11b+) (Vremec et al., 2000). Both subtypes 
differ in cytokine production and immune functions (Shortman and Heath, 
2010). CD8α- DCs can be segregated into CD4+CD8α- and CD4-CD8α- 
subsets.  
There are an additional two DC subsets in lymph nodes that are not found in 
the spleen because they are tissue-derived migratory DCs. They are 
distinguished by their expression of CD11b and CD103 (CD4-CD8α- CD11b+ 
CD103- and CD8α- CD11b- CD11b- CD103+) (Henri et al., 2001). With the 
exception of mesenteric lymph node (Bogunovic et al., 2009) and pancreatic 
islet lymph node (Yin et al., 2012), CD11b+ CD103+ DCs do not exist in other 
draining lymph nodes. Another subset, Langerhans cells (LCs) (CD8α- 
CD11b+ CD205+ Langerin+) are present only in cutaneous draining lymph 
nodes (Bursch et al., 2007; Merad et al., 2008).  
On the other hand, unique in their ability to produce high amounts of 
interferon-α (IFN-α), pDCs are classified as non-conventional DCs (Kushwah 
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and Hu, 2011; Shortman and Naik, 2007). pDCs are thus named for their 
plasma cell-like morphology and their expression of the B cell marker, B220. 
Not only distinct in function, pDCs are markedly different in their phenotype 
(B220+ Gr-1+ CD11clow) (Martin et al., 2002; Nakano et al., 2001) and can be 
further characterized by expression of Siglec-H (Blasius et al., 2006a), CCR9 
(Wendland et al., 2007), PDCA-1 (Bierly et al., 2008; Blasius et al., 2006b) 
and lymphocyte activation marker-3 (LAG-3) (Workman et al., 2009).  
 
1.7.3 DCs in atherosclerosis 
 
DCs are key players of VALT and form immunological synapses with T 
lymphocytes in inflammatory infiltrates of atherosclerotic lesions and aortic 
aneursyms (Bobryshev and Lord, 2001). During steady state, indigenous DC 
populations can be found at the media-adventitia junction (Han et al., 2008; 
Pryshchep et al., 2008). They are capable of sensing pathogens and respond to 
TLR ligands such as LPS in bioengineered arteries. They could induce 
autologous T cell activation and accumulation, leading to breakdown of self-
tolerance (Han et al., 2008).   
Most vascular DCs in human atherosclerotic lesions exhibit a mature 
phenotype (Kawahara et al., 2007). Activated DCs in the plaque in close 
contact with T cells often express markers such as CD40, CD83, CD86 and 
HLA-DR that is used for co-stimulation in T cell activation. Vascular DCs 
also produced chemokines such as CCL19 and CCL21 that can regulate T cell 
trafficking into the lesion (Erbel et al., 2007). These DC-T cell interactions 
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were shown to promote atherosclerosis by production of pro-inflammatory 
cytokines such as TNF-α and IFN-γ which sustained chronic inflammation 
(Koltsova et al., 2012).  
Giant cell arteritis (GCA), a granulomatous vasculitis that affects medium- 
and large-sized arteries is remarkably similar to atherosclerosis. Vascular DCs 
can be found at the media-adventitia border and they are enriched and 
activated in arteries affected by GCA. Moreover, activated DCs in GCA 
produced CCL19 and CCL21, leading to their immobilization in GCA lesions 
(Krupa et al., 2002; Ma-Krupa et al., 2004).  
Vascular DCs may also play a role in cholesterol homeostasis as short-term 
depletion of these cells has been shown to enhance hypercholesterolemia 
(Gautier et al., 2009).  
 
1.7.4 Heterogeneity of DCs in atherosclerosis 
 
Earlier studies on DCs in the aorta in atherosclerosis focused on generic 
CD11c+ DCs (Choi et al., 2009; Galkina et al., 2006; Jongstra-Bilen et al., 
2006). However, it is increasingly obvious that aortic DCs are also 
heterogeneous.  
Resident aortic DCs (CD11c+ CD11b- CD68+ MHC-II+ 33D1+) are capable of 
lipid uptake, which contributes to foam cell formation (Paulson et al., 2010).  
They accumulate in atherosclerotic lesions by proliferation in response to GM-
CSF (Zhu et al., 2009).  
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In contrast, CCL17+ DCs (CD11c+ CD11b+ CD8α- CD115- F4/80- PDCA-1-) 
are not found in steady state but accumulates during atherosclerotic lesion 
development and are found to drive the disease by limiting regulatory T cell 
homeostasis (Weber et al., 2011). 
pDCs have been observed in human and murine atherosclerotic lesions and the 
role of pDCs in experimental atherosclerosis is controversial (Grassia et al., 
2013). Although they are rare in atherosclerotic plaques, specific depletion of 
pDCs in Ldlr-/- mice worsened atherosclerotic lesions due to loss of 
suppressive effect of pDCs on T cell proliferation in the periphery 
(Daissormont et al., 2011). On the contrary, in apoE-/- mice, depletion of pDCs 
reduced atherosclerosis by dampening T cell activation and induction of 
systemic reduction of pro-atherosclerotic mediators such as IL-12 (Macritchie 
et al., 2012). The contradicting data may be due to the use of different 
depleting antibodies and mouse models but it does not negate the fact that 
pDCs are one of the players in atherosclerosis.  
Following the widely recognized characterization of non-lymphoid tissue DC 
subsets (Helft et al., 2010), two DC subsets, namely CD103+ (CD11b- F4/80-) 
and CD11b + (CD103- F4/80+) DC subsets have been described in normal 
murine aorta and both were expanded in atherosclerotic Ldlr-/- mice (Choi et 
al., 2011). In this latter study, lack of CD103+ DCs increased atherosclerotic 
lesions and was associated with a reduction in regulatory T cells, suggesting 
that CD103+ DCs are athero-protective.  
Lastly, not to be confused with CCL17+ DCs, CD11b+ CD11c+ DCs that 
express F4/80 antigen are another DC subset that can be found accumulating 
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in atherosclerotic aorta. They are capable of prolonged interaction with CD4+ 
T cells, leading to T cell activation, proliferation and production of pro-
inflammatory cytokines. This in turn supported foam cell formation by 
increasing uptake of modified lipoproteins by macrophages (Koltsova et al., 
2012).





Monocytes are circulating blood leukocytes derived from bone marrow 
progenitors that can further differentiate into macrophages and dendritic cells 
(DCs). They are also one of the key players in the initiation of atherosclerosis 
development. 
 
1.8.1 Phenotype and function of murine monocyte subsets  
 
Circulating monocytes in mice express CD115, F4/80 and CD11b. They are 
divided into two subsets: classical Ly6Chi and non-classical Ly6Clow 
monocytes (Geissmann et al., 2003). The subsets are further distinguished by 
the chemokine receptors and adhesion molecule they express (Shi and Pamer, 
2011). Ly6Chi monocytes express CCR2, CD62L and have low expression of 
CX3CR1 whereas Ly6Clow monocytes express high levels of CX3CR1 but do 
not express CCR2 and CD62L (Auffray et al., 2009b).  
Developmentally, Ly6Chi monocytes are precursors of Ly6Clow monocytes. 
Based on depletion by clodronate liposomes, Ly6Chi monocytes were found to 
repopulate first in circulation and give rise to Ly6Clow monocytes 
(Sunderkotter et al., 2004).  
In terms of function, Ly6Chi monocytes are specifically recruited to 
inflammatory sites where they give rise to effector APCs (Auffray et al., 
2009a; Geissmann et al., 2003; Palframan et al., 2001; Serbina and Pamer, 
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2006; Sunderkotter et al., 2004; Zigmond et al., 2012), thus earning their title 
as “inflammatory” monocytes. Ly6Chi monocytes depend on CCR2 for 
mobilization from bone marrow into the circulation (Tsou et al., 2007).  
On the other hand, Ly6Clow monocytes are termed as “resident” monocytes as 
they reside longer in peripheral tissues in the absence of inflammation 
(Geissmann et al., 2003; Sunderkotter et al., 2004). They depend on CX3CR1 
for homing to peripheral tissues (Geissmann et al., 2003). The function of 
Ly6Clow monocytes was only recently described. Due to observations that this 
monocyte subset exhibit “crawling” behavior and stay within blood vessels in 
steady state, they appear to function as patrollers of blood vessels (Auffray et 
al., 2007). Owing to their patrolling behavior, Ly6Chi monocytes are able to 
extravasate rapidly in response to tissue damage, aseptic wounding and 
peritoneal infection with Listeria monocytogenes and are responsible for early 
inflammatory response against Listeria monocytogenes. 
The dichotomy in function of the two monocyte subsets was also shown in  the 
healing mycocardium whereby Ly6Chi monocytes were first recruited with 
inflammatory functions to digest damaged tissue and Ly6Clow monocytes were 
mobilized later to attenuate inflammation and promote healing (Nahrendorf et 
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1.8.2  Monocyte subsets in atherosclerosis 
 
Prior to lesion development, monocytes are the major immune cell component 
in the intima of lesion-prone areas and constitute the major source of foam 
cells in early lesion formation (Gerrity, 1981). Although neutrophils are 
known to be involved in atherosclerosis (Soehnlein, 2012), we focused on 
monocytes due to their developmental relationship with DCs. It has been 
shown that neutrophilia occurred as early as 4 weeks after high fat diet 
induction in the bone marrow and aorta under the influence of granulocyte 
colony-stimulating factor (G-CSF). However, neutrophil count in the aorta 
decreased over time during atherosclerosis progression (Drechsler et al., 2010) 
and almost returned to baseline count after 16 weeks of high fat diet. In 
addition, the study has shown that in comparison to mice with normal white 
blood count after 1 month of high fat diet, the reduction of CD45+ leukocytes 
in the aorta of neutropenic mice reduced mainly neutrophils, inflammatory 
monocytes and macrophages. However, aortic DCs and Ly6Clow monocytes 
were unaffected.  
The importance of monocytes in atherosclerosis is highlighted when plaque 
burden is reduced in rabbits administered with clodronate liposomes to deplete 
circulating monocytes (Ylitalo et al., 1994). In addition, depletion of CD11b+ 
cells resulted in a reduction of monocytes and plaque lesion size during initial 
phase of atherosclerosis (Stoneman et al., 2007). However, depletion by 
CD11b is not specific and may affect other populations that express it. In a 
disease regression model, plaque macrophage content was reduced and this 
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effect was attributed to suppression of monocyte recruitment (Potteaux et al., 
2011). 
Similar to Listeria monocytogenes infection, monocytosis developed in 
hypercholesterolemic apoE-/- mice (Ingersoll et al., 2011). Interestingly, 
hypercholesterolemia led to a skewing towards Ly6Chi monocytosis, 
disrupting the 50:50 ratio of Ly6Chi:Ly6Clow monocyte profile in the blood 
(Swirski et al., 2007; Tacke et al., 2007). Ly6Chi monocytosis occurred as a 
result of increased survival, cell proliferation and impaired conversion of 
Ly6Chi to Ly6Clow monocytes (Swirski et al., 2007). However, under moderate 
hypercholesterolemia conditions, both Ly6Chi and Ly6Clow monocytes 
accumulated in circulating blood (Combadiere et al., 2008). In a recent study, 
ApoE complementation to apoE-/- mice reduced monocytosis, suggesting that 
ApoE itself regulates monocytosis (Murphy et al., 2011).  
Since both monocyte subsets possess different chemokine receptor profile, 
studies were undertaken to investigate their dependence on chemokines in 
entry into atherosclerotic plaques. Despite expressing low levels of CX3CR1, 
Ly6Chi monocytes unexpectedly depend on CX3CR1 to enter atherosclerotic 
lesions (Tacke et al., 2007). Ly6Chi monocytes were also dependent on CCR2 
for trafficking to atherosclerotic plaques at two levels: one at the level of 
egress from the bone marrow and the other is trafficking from blood into 
plaques. In the same study, Ly6Clow monoctyes were surprisingly independent 
of CX3CR1 for their accumulation in atherosclerotic plaques. Neither were 
they dependent on CCR2 but their migration into the atherosclerotic plaques 
was partially dependent on another chemokine receptor, CCR5. Thus, to 
abolish both Ly6Chi and Ly6Clow monocyte accumulation in atherosclerotic 
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plaques, combined inhibition of CCL2, CX3CR1 and CCR5 is needed. Indeed, 
inhibition of all three signals abrogated monocytosis and reduced lesion size 
(Combadiere et al., 2008). 
 
1.9 Monocyte-derived cells 
 
Monocytes are plastic cells that can terminally differentiate into macrophages 
and dendritic cells (Gordon and Taylor, 2005; Leon and Ardavin, 2008). They 
were initially thought to only give rise to tissue macrophages at steady state 
(Dominguez and Ardavin, 2010).  
However, evidence of monocyte-derived DCs (MoDCs) at steady state is 
becoming apparent. Adoptive transfer of monocytes into recipient mice that 
were first depleted of DCs showed efficient seeding and differentiation of 
donor monocytes into DCs in lamina propria (Bogunovic et al., 2009) and lung 
parenchyma but not into splenic cDCs (Varol et al., 2007). Furthermore, 
employing latex bead labeling for monocytes, Ly6Chi and Ly6Clow monocytes 
were shown to differentiate into two different DC subsets, CD103+ and 
CD11b+ DCs respectively in the lung at steady state (Jakubzick et al., 2008). 
Ly6Clow monocytes are also able to differentiate into lung macrophages at the 
same time (Landsman et al., 2007). Otherwise, recovery of adoptively 
transferred monocytes proved to be challenging at steady state in other non-
lymphoid tissues (Ginhoux et al., 2009). Recently, MoDCs in skeletal muscles 
at steady state have been identified using the marker, CD64 (Langlet et al., 
2012), which perhaps will pave the way in studying MoDCs at steady state.  
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Nonetheless, the discovery of this cell type in vivo was originally first made 
during inflammatory conditions because of the large numbers of MoDCs 
generated during inflammation. Of interest, a DC subset that arises during 
inflammation is the TNF-α/iNOS-producing DCs (TipDCs) and is important in 
the clearance of Listeria monoctyogenes infection in mice infected with the 
bacteria (Serbina et al., 2003). TipDCs arise from Ly6Chi monocytes and 
express CD11b and Mac-3. They have high expression of MHC class II and 
Ly6C and low expression of CD11c. As its name suggests, they produce high 
levels of TNF-α and iNOS. TipDCs are required for CD8+ T cell response in 
influenza virus infection (Aldridge et al., 2009) and contribute to pathogenesis 
of psoriasis (Lowes et al., 2005). They can also be naturally occurring in 
MALT where they regulate IgA production important for gut homeostasis 
(Tezuka et al., 2007). 
In atherosclerosis, Ly6Chi monocytes were shown to differentiate into 
macrophages (Swirski et al., 2007) whereas Ly6Clow monocytes were 
associated with CD11c+ DCs in atherosclerotic plaques (Tacke et al., 2007). 
Consequently, different monocyte subsets are able to differentiate into 
different cell types during steady state and inflammation. 
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1.10 Aims and rationale 
 
Heterogeneity of DCs in atherosclerosis is a recent insight. The disparate 
characterization of DC subsets in atherosclerotic aorta and the use of different 
experimental mouse models of atherosclerosis make it challenging to identify 
and compare findings. However, the recent classification of DC subsets in 
non-lymphoid tissues provides a platform for a standardized classification of 
DC subsets in atherosclerotic aorta. Insofar, the focus of literature has been on 
CD103+ DC subsets. Little is known about the CD11b+ DC subset in the  
apoE-/- mouse model. In this study, we first examined and characterized 
CD11b+ DCs at steady state, whether they accumulate in apoE-/- mouse model 
and their localization. Subsequently, once we had established their existence 
and accumulation in atherosclerotic apoE-/- aorta, we investigated the origin of 
these cells and the mechanisms by which they accumulate. Lastly, the function 
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Chapter 2 – Materials and Methods 
2.1 Mouse models 
Heterozygous CX3CR1+/gfp and transgenic Mafia [C57BL/6-Tg(Csf1r-EGFP-
NGFR/FKBP1A/TNFSRSF6)2Bck/J] (Burnett et al., 2004) were kindly 
provided by Dr. Florent Ginhoux (Singapore Immunology Network, 
A*STAR). ApoE-/- , Ldlr-/- , CD45.1 and CD45.2 wild-type (WT) male mice 
on a C57/BL6 background were obtained from The Jackson Laboratory (Bar 
Harbor, ME, USA). ApoE-/-, Ldlr-/- and CD45.2 wild type littermates were fed 
normal chow diet (18% protein and > 5% fat; Harlen Teklad, Madison, Wl, 
USA). At 6 weeks of age, mice were switched to a high-fat diet (21% milk fat 
and 0.15% cholesterol; Harlan Teklad) for 18 to 22 weeks, corresponding to 
24 to 28 weeks of age unless otherwise stated. Mice were maintained under 
specific pathogen-free conditions with free access to food and water within 
National University of Singapore’s animal housing unit. All studies were 
approved by National University of Singapore and Biological Resource Center 
Institutional Animal Care and Use Committee.  
 
2.2 Treatment of Mice  
2.2.1 Treatment of mice with Ezetimibe 
Oral administration of cholesterol-lowering drug, Ezetimibe (5mg/kg/day) or 
vehicle (corn oil) to apoE-/- and matching WT mice started at 12 weeks of age 
when the disease is well advanced and was maintained for 12 weeks.  
 




2.2.2 Treatment of mice with neutralizing anti-GM-CSF antibody 
50µg of neutralizing anti-GM-CSF antibody (R&D Systems, MN, USA) was 
injected intraperitoneally per mouse at the age of 16-18 weeks for 4 days 
before sacrifice 24 hours later after last injection.  
 
2.3 Isolation of Cells 
2.3.1 Isolation of cells from murine aorta  
Mice were sacrificed by CO2 inhalation and aortas were perfused through the 
heart with 20ml of PBS and thereafter with 10ml of Ca2+/Mg2+ Hank’s 
Buffered Salt Solution (HBSS) medium (Sigma, MO, USA) containing 0.1% 
BSA. Adventitial fat and surrounding lymph nodes were removed and aortas 
were dissected under a stereomicroscope. Single cells were prepared by 
cutting aortas into small pieces and digesting in Ca2+/Mg2+ HBSS containing 
1mg/ml Collagenase Type IV (Gibco, CA, USA) at 37oC for 2 hours. Digested 
aortas were further disaggregated by passing through a syringe with 19G 
needle (BD Biosciences, NJ, USA). Cell suspensions were then filtered 
through a nylon net filter (Millipore, MA, USA) and washed before 
proceeding to staining for flow cytometry. In most experiments, aortas from 2 
mice were pooled and analyzed for flow cytometry unless otherwise stated.  
2.3.2 Isolation of bone marrow cells  
Femurs and tibiae of mice were cut and the marrow was flushed out with 
RPMI-1640 (Sigma) complete medium (Appendix 1). The bone marrow 
suspension was passed through a 30µm cell strainer and centrifuged at 1200 
rpm for 5 minutes. The cell pellet was lysed with 0.9% ammonium chloride 




solution (Appendix 1) to remove red blood cells, washed with PBS and 
resuspended in RPMI-1640 complete medium unless otherwise stated. Viable 
cells were counted with trypan blue (Sigma) viability assay. 
2.3.3 Isolation of bone marrow monocytes  
Bone marrow cells were isolated as described in Section 2.3.2 except lysis of 
red blood cells was not performed as advised by manufacturer. Cell pellet was 
resuspended in EasySepTM buffer (Appendix 1). Monocytes were pre-enriched 
by EasySepTM immunomagnetic negative selection using the mouse monocyte 
enrichment kit (STEMCELL, Vancouver, BC, Canada) following 
manufacturer’s instructions. Briefly, the bone marrow cells were incubated 
with rat serum to block non-specific binding and EasySepTM Mouse Monocyte 
Enrichment Cocktail was added to label unwanted cells (non-monocytes). This 
was followed by a washing step and incubating the cell suspension with 
EasySepTM Biotin Selection Cocktail. EasySepTM D Magnetic Particles were 
added to form tetrameric antibody complexes with unwanted cells. These 
magnetically labeled cells were then separated in the presence of a magnetic 
field, allowing unlabeled monocytes to pass through.  
2.3.4 Isolation of cells from blood 
Where mice were not sacrificed immediately, facial vein bleed was performed. 
Otherwise, cardiac puncture was employed to obtain blood. Blood collected 
was prevented from coagulating by adding 40µl of 0.5M EDTA. Thereafter, 
blood was lysed with Pharm LyseTM (BD), washed and resuspended in FACS 
buffer for staining.    
 




2.3.5 Isolation of cells from spleen 
Spleen was removed and digested with 1mg/ml Collagenase Type IV at 37oC 
as before (Section 2.3.1) for 1 hour and 30 minutes. Tissue pieces were then 
passed through a 19G needle and 70µm cell strainer (BD Biosciences) to 
obtain a homogeneous cell suspension. Cell suspension was centrifuged at 
1200 rpm for 5 minutes and erythrocytes were lysed with 0.9% ammonium 
chloride solution, washed and resuspended in FACS buffer.  
 
2.4 Generation of bone marrow-derived dendritic cells  
Generation of bone marrow-derived dendritic cells has been described 
previously (Inaba et al., 1992). Briefly, after isolation of bone marrow cells 
(Section 2.2.2), cells were counted and cell concentration was adjusted to 1 x 
106/ml in RPMI-1640 complete medium. Conditioned medium from J558L 
cell line which contained granulocyte-macrophage colony-stimulating factor 
(GM-CSF) was added at 1:30 dilution. The cells were then plated at 1ml per 
well in a 24-well plate and fed every 2 days. On day 6 of culture, the cells 
were either left unstimulated or stimulated with 1µg/ml Escherichia coli LPS, 
serotype O111:B4 (Sigma). 
 
2.5 Adoptive cell transfer - transfer of CD45.1 monocytes into congenic 
CD45.2 apoE-/- recipients 
4 to 5 x 106/200µl of CD45.1+ bone marrow monocytes (Section 2.3.3) were 
intravenously injected into the lateral tail of CD45.2+ apoE-/- recipient mice.  




2.6 Generation of chimeric mice 
CD45.2+ WT mice were lethally irradiated (2 times, 4.8 Gy, 3 hours apart) at 6 
weeks of age and reconstituted with 5 x 106 cells of CD45.1+ bone marrow 
cells.  
 
2.7 Proliferation study  
Mice were injected intraperitoneally with 1mg EdU (Invitrogen) and 
euthanized by CO2 inhalation after 2 hours or 12 hours. Cells from aorta and 
blood were prepared as described in Section 2.3. Detection of EdU for flow 
cytometry is detailed in Section 2.9.4. 
 
2.8 Culture of cell line 
J558L cell line is a transfected cell line which secretes GM-CSF into its 
culture supernatant. When cells were first thawed out, they were cultured in 
IMDM complete medium with Geneticin (G418) (Life Technologies, CA, 
USA). Once cell line is established, cells were propagated in IMDM complete 
medium without G418. Culture supernatant from the cells was collected, 
sterile filtered and stored at -80oC until needed for generation of BMDCs.  
 
2.9 Flow cytometry 
The panel of antibodies used for this study is listed under Appendix 2.  
 




2.9.1 Viable cell staining for flow cytometry 
Initially, DAPI was used to discriminate between the live and dead cells 
during flow cytometry. Cells were resuspended in DAPI solution just before 
flow cytometry acquisition. DAPI negative cells were gated as viable cells. 
Otherwise, a LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life 
Technologies) was used according to manufacturer’s instructions. Briefly, 
cells were resuspended in 1ml of PBS and 1 µl of Aqua dye was added, mixed 
well and incubated for 30 minutes. Cells were then washed with PBS twice 
before proceeding to surface or intracellular staining for flow. Aqua negative 
cells were gated as viable cells. 
2.9.2 Surface staining for flow cytometry 
Cells were stained with fluorochrome-conjugated primary antibodies and 
matched isotype control antibodies as required in FACS buffer (Appendix 1). 
Where non-conjugated primary antibodies were used, suitable fluorochrome-
conjugated secondary antibodies were applied.  
2.9.3 Intracelluar staining for flow cytometry 
Intracellular staining of cells for flow cytometry was performed with 
Intracellular Fixation and Permeabilization Buffer Set (eBioscience, CA, 
USA) according to manufacturer’s instructions. Briefly, after surface antigen 
staining was performed (Section 2.9.2), cells were fixed by adding fixation 
buffer for 10 minutes. Fixed cells were then permeabilized by washing in 1x 
permeabilization buffer. Permeabilized cells were resuspended with antibody 
or matched isotype control in 1x permeabilization buffer. Cells were washed 
with 1x permeabilization buffer and resuspended in PBS prior to running flow. 




2.9.4 Detection of EdU by flow cytometry 
Detection of EdU was carried out with Click-iT® EdU Flow Cytometry Assay 
Kit (Life Technologies). Prior to staining for EdU, single cells obtained were 
stained with a Fixable Live/Dead cell stain as previously described. Surface 
antigens of cells were stained as per normal except staining with PE or PE-
tandem conjugated antibodies were only performed after detection of EdU. 
Cells were fixed with fixative provided in the kit and permeablized with a 
reaction cocktail (containing a fluorescent azide dye to reveal EdU positive 
cells) as stated in manufacturer’s data sheet and washed before proceeding on 
to staining with PE or PE-tandem dyes.  
2.9.5 Cell counting by beads for flow cytometry 
Prior to use, CountBright® Absolute Counting Beads (Life Technologies) 
were vortexed to ensure consistent concentration of beads. 10µl of beads was 
added to suspension and mixed well. The counting beads can be gated on an 
empty fluorescence channel and will appear at the upper right corner of a dot 
plot. To ensure an accurate determination of cell numbers, at least 1,000 bead 
events were acquired. The number of cells in each sample was calculated 
based on the following formula: 
No of cells = No of cell events/No of bead events x No of beads 
where the no of beads is obtained from a predetermined concentration stated 
on the product (can vary between lots) multiplied by volume of bead added to 
samples  
 




2.9.6 Acquisition and analysis for flow cytometry 
Stained cell suspensions were acquired on either LSR Fortessa, LSR II (BD 
Biosciences, CA, USA) with FACS Diva software or on Cyan flow cytometer 
(Dako, Denmark) with Summit software. Data was analyzed post-acquisition 
with Flowjo software (Treestar, OR, USA).  
 
2.10 Immunofluorescence staining 
2.10.1 Preparation of tissue sections  
Aortas were perfused with PBS and fixed in 2% w/v paraformaldehyde with 
30% w/v sucrose for at least 6 hours to overnight at 4oC, washed in PBS on a 
rotator for 2 hours and embedded in tissue freezing compound (Sakura 
Finetek, CA, USA). 5µm thick tissue sections were cut on a cryostat machine 
(Leica, Wetzlar, Germany) and mounted on polysine-coated slides (Thermo 
Scientific, MA, USA) and stored at -20oC.  
2.10.2 Staining of tissue sections 
Prior to staining, slides were air-dried for at least 2 hours. Sections were first 
blocked with PBS supplemented with 0.2% BSA for 10 minutes. Primary 
antibodies were diluted in PBS containing 1% normal mouse serum (Jackson 
ImmunoResearch Laboratories, PA, USA) and applied to tissue sections kept 
in humidified chambers for 1 hour at room temperature or overnight at 4oC. 
Following this, slides were washed 3 times in PBS, 5 minutes each. Suitable 
fluorochrome-conjugated secondary antibodies raised in different species with 
minimal cross-reactivity were similarly diluted in PBS containing 1% normal 
mouse serum and added to tissue sections for 1 hour at room temperature in 




the dark. The slides were washed 3 times in PBS, 5 minutes each and 
subsequently stained with DAPI (1:20,000) (KPL, Maryland, USA) for 5 
minutes followed by a final wash in PBS for 5 minutes. Slides were then 
mounted with cover slips using Dako fluorescent mounting medium (Dako).  
A list of antibodies used for immunofluorescence staining can be found in 
Appendix 3.  
2.10.3 Staining of tissue sections with tyramide amplification 
When tyramide signal amplification (Perkin Elmer) was needed, an additional 
blocking with 3% hydrogen peroxide to quench endogenous peroxidase was 
performed for 10 minutes after blocking with BSA. Slides were then washed 
and primary antibodies applied in the same manner. After washing off the 
primary antibodies, tissue sections were incubated with peroxidase-conjugated 
secondary antibodies diluted in PBS with 1% normal mouse serum for 1 hour 
at room temperature in the dark. The slides were washed in PBS for 3 times, 5 
minutes each. Where double signal amplification was required for 2 different 
antigens, an additional blocking with 3% hydrogen peroxide was performed 
before the second peroxidase-conjugated secondary antibody was added. 
Fluorochrome-conjugated tyramide solution (1:50) was prepared using 
tyramide amplification diluents according to manufacturer’s instructions and 
applied to sections after incubation with peroxidase-conjugated secondary 
antibodies. Slides were then washed in PBS containing 0.05% v/v Tween-20 
for 3 times, 5 minutes each before mounting with Dako fluorescent mounting 
medium as before.  
 




2.10.4 Preparation of whole mounts 
Aortas were perfused with PBS and followed by 2% w/v paraformaldehyde 
with 30% w/v sucrose. Surrounding adipose tissue was dissected and aorta 
samples were fixed in 2% w/v paraformaldehyde with 30% w/v sucrose 
overnight at 4oC, washed in PBS twice and stored at 4oC.  
2.10.5 Staining of whole mounts 
Endogenous peroxidase in whole aorta samples was quenched by 3% 
hydrogen peroxide for 2 hours in the dark at 4oC and washed with PBS for 1 
hour at room temperature. Samples were blocked with blocking buffer (PBS 
with 0.5% BSA and 0.3% v/v Triton X-100) at 4oC overnight. Thereafter, 
samples were washed in washing buffer (PBS with 0.2% BSA, 0.1% v/v 
Triton X-100 and 0.1M glycine) for an hour on a rotator at room temperature. 
Staining with antibodies were then carried out as described in Section 2.9.2 
and 2.9.3 with the exception that antibodies were diluted in blocking buffer 
and incubated overnight at 4oC. When tyramide amplification was performed, 
samples were incubated with fluorochrome-conjugated tyramide solution for 
at least 3 hours before washing. The aorta samples were cut open and flattened 
segments were mounted on glass slides with Dako fluorescent mounting 
medium.  
2.10.6 Acquisition of images 
Images were captured with a fluorescence microscope (Axio imager.Z1, 
Axiocam HRM camera; Carl Zeiss Micro Imaging, Inc., Jena, Germany). 
Images were processed with Axiovision software.  
 




2.11 Quantitative gene expression analysis 
2.11.1 RNA extraction and Reverse-Transcriptase Polymerase Chain 
Reaction (RT-PCR) 
Adventitial fat was removed from aorta samples and aortas were divided into 
thoracic and abdominal regions before placing them into RNAlaterTM (Qiagen, 
CA, USA) for archival storage at -80oC until homogenization can be 
performed. Samples were transferred into Trizol® solution (Invitrogen) and 
homogenized with Omni Bead Ruptor Homogenizer (Omni International, GA, 
USA). Extraction of total RNA was performed with Nucleospin® RNA II kit 
(Macherey-Nagel, Dueren, Germany) according to the manufacturer’s 
instructions. Messenger RNA (mRNA) concentrations and purity were 
measured with Nanodrop 1000 SpectrophotometerTM (Thermo Scientific). RT-
PCR was carried out using TaqMan® Reverse Transcription Reagents 
(Applied Biosystems, CA, USA) and Thermal Cycler (Applied Biosystems) as 
follows: 
1. A reaction mixture consisting of:  
a. 1000ng mRNA 
b. 1.25µM oligo-dT  
c. 1.25µM random hexamer  
d. 2.5mM dNTPS (500µM per dNTP) 
was prepared.  




2. Tertiary structure of mRNA was first linearized by placing the reaction 
mixture under the following conditions:  
Step 1 2 3 
Time 5 minutes 2 minutes Infinite 
Temperature 65oC 4oC 4oC 
 
3. A master mix containing the following reagents:  
 Working Concentration 
10x RT buffer 1x 
25mM MgCl2 5.5mM 
RNase Inhibitor (20U/L) 0.4U/µl 
Multiscribe Reverse Transcriptase 1.25U/µl 
 
was added to the previous reaction mixture. 
4. The following thermal cycling parameters was used for the final 
mixture for cDNA synthesis: 
 
 










Time 10 minutes 30  minutes 5 minutes Infinite 
Temperature 25oC 48oC 95oC 4oC 
 
2.11.2 Real – time polymerase chain reaction (qPCR) 
A mixture containing: 1µl of template cDNA, 10µl of iTaqTM SYBR® Green 
supermix with ROX (Biorad, CA, USA), 250nM gene-specific primers and 
7µl of RNase-free water was prepared and real-time PCR was performed in a 
7500 Real-Time PCR System (Applied Biosystems) under the following 




Cycle (40 cycles) 
Denaturation Annealing Extension 
Temperature 95oC 95oC 55oC 72oC 
Time 10 minutes 30 seconds 1 minute 1 minute 
 
Data was acquired at the extension phase. After 40 cycles of PCR, a 
dissociation curve analysis was also carried out by cooling to 55oC for 1 
minute and increasing the temperature to 95oC. Measurement of the changes in 




fluorescence was measured simultaneously and plotted against temperature, 
allowing the discrimination between specific and non-specific PCR products. 
Target gene expression was analyzed by normalizing to expression of the 
endogenous control GAPDH.  List of genes and primer sequences can be 
found in Appendix 4.    
 
2.12 Enzyme-Linked Immunoabsorbent Assay (ELISA) 
Aortas removed of adventitial fat were harvested and placed in a lysis 
solution, RIPA buffer (Sigma) with protease inhibitor cocktail (Roche 
Diagnostics, IN, USA) and homogenized with Omni Bead Ruptor 
Homogenizer. Supernatants were collected after centrifugation for 10 minutes 
at 4oC at 14000g and measured for GM-CSF using a commercial GM-CSF 
ELISA kit (R&D Systems, MN, USA) according to manufacturer’s 
instructions.  
 
2.13 Statistical analysis 
Data were analyzed with Prism 5 (GraphPad Software, Inc., CA, USA). Mann-
Whitney U test or unpaired Student’s t test with two-tailed distributions was 
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Atherosclerosis is an inflammatory disease of the aorta characterized by lipid 
accumulation and infiltration of immune cells (Hansson and Hermansson, 
2011). Among the heterogeneous population of immune cells present in the 
atherosclerotic plaque, dendritic cells are known to be the most potent antigen-
presenting cell in the immune system. The discovery of vascular DCs in 
normal arteries of young children (Millonig et al., 2001a) and accumulation of 
these cells in human adult atherosclerotic lesions (Bobryshev and Lord, 
1995b) suggest that DCs may have a role to play in the developing plaques.  
Similar to human atherosclerosis, accumulation of DCs in a mouse model of 
atherosclerosis (Bobryshev et al., 2001) was observed. Vascular DCs were 
first detected by flow cytometry in the mouse using markers such as CD11c 
and MHC class II (Choi et al., 2009; Galkina et al., 2006). However, CD11c 
has been proven to be a non-specific marker for DCs as both macrophages and 
DCs can express high levels of CD11c in the murine lung (Jakubzick et al., 
2008; Vermaelen et al., 2001). In addition, CD11c+ vascular DCs in the 
intimal layer of murine aorta were shown to be CD68+, a classical marker for 
macrophages (Jongstra-Bilen et al., 2006), showing that CD11c alone is 
insufficient to delineate DCs.  




With the recent emergence of non-lymphoid tissue DC subsets (Helft et al., 
2010), where CD11b+ and CD103+ DC subsets have been identified, the need 
to redefine DCs in the murine aorta arises. In a recent report, both CD11b+ and 
CD103+ DC subsets were described in the murine aorta (Choi et al., 2011). 
However, this study did not extensively characterize the DC subsets and their 
origin at steady state and focused on the function of CD103+ DC subset in the 
Ldlr-/- mouse model of atherosclerosis. Furthermore, whether the same DC 
subsets exist in the apoE-/- mouse model of atherosclerosis and if a particular 
DC subset or both accumulate in this model remains largely unknown.  
Hence, we were interested in establishing a comprehensive phenotypic 
characterization of the DC subsets and investigating the origin of these DCs in 
the murine aorta at steady state. Based on steady-state studies, we also 
investigated the DC subsets in the apoE-/- mouse model of atherosclerosis. 





3.2.1  Similar non-lymphoid tissue dendritic cell subsets are present in 
normal (or healthy) murine aorta  
 
Akin to other non-lymphoid tissues (Helft et al., 2010) , we show that I-A+ 
CD11c+ DCs in the murine aorta at steady state can be divided into two 
populations, CD11b+ and CD103+  (Figure 3.1A). Moreover, CD11b+ DC 
subset is the dominant DC subset in the murine aorta (approximately 70% of 
CD11b+ DCs: 10% of CD103+ DCs) as observed in the other non-lymphoid 
tissues. However, there is no evidence of a discrete population of CD11b+ 
CD103+ DC subset in the murine aorta as compared to murine intestine 
(Bogunovic et al., 2009).  Consistent with previous report (Ginhoux et al., 
2009), the CD11b+ DC subset which lacks CD103 expression, expressed high 
levels of F4/80 and SIRP-α (Figure 3.1B). Using the heterozygous 
CX3CR1+/gfp and Mafia mouse models, we were able to further characterize 
the two DC subsets. Expectedly, CD11b+ DC subset expressed high levels of 
CX3CR1 and CD115 whereas CD103+ DC subset did not express these 
receptors (Figure 3.1B). The DC subsets present in the aorta resembled most 
non-lymphoid tissues in that the CD11b+ CD103+ DC subset present in lamina 
propia remains unique to that tissue site possibly due to the existence of 
microbiota. 
















Figure 3.1. DC subsets present in murine aorta at steady state.  
(A) After gating for live and singlet cells, aortic DCs were identified as 
CD45+, I-A+ and CD11c+ cells and can be distinguished into CD11b+ and 
CD103+ DCs. (B) Histograms show expression levels (grey) of Sirp-α, F4/80, 
CD115 and CX3CR1 with controls (open) on CD11b+ (top panel) and CD103+ 
DCs (bottom panel). Data shown are representative of 3 independent 
experiments of 2-3 mice in each experiment.   




3.2.2 Aortic DCs are localized in atherosclerosis-prone regions of the 
murine aorta at steady state 
 
Since the development of atherosclerotic lesions occurs at sites of disturbed 
blood flow, the aorta is known to be divided into atherosclerosis-prone and 
atherosclerosis-resistant regions (Jongstra-Bilen et al., 2006; Mullick et al., 
2008). Vascular DCs are known to accumulate in atherosclerosis-prone 
regions. The localization of the DC subsets in murine aorta at steady state has 
so far been confined to the aortic sinus, cardiac valves and aortic ostium (Choi 
et al., 2009). Aorta whole mount was cut open longitudinally and laid flat onto 
microscopic slides for en face analysis. We observed DC subsets being 
situated at atherosclerosis-prone areas with this method. They were also 
mainly located in the intimal layer of the murine aorta. Consistent with the 
results from flow cytometry, the CD11b+ DC subset was the dominant 
population in the murine aorta and most of them have a dendritic-like 
morphology (Figure 3.2). 







Figure 3.2. Aortic DCs are localized in atherosclerosis-susceptible regions in WT mouse.  
Whole mount (adventitial layer removed) immunofluorescent staining revealed the presence of aortic DCs in the intimal layer of aortic arch. 
CD11b+ (arrows) and CD103+ (arrowheads) DCs can both be found in this region. Elastic fibers of the aorta are auto-fluorescent; magnification 
200X. Scale bar 50µm. 
I-A CD11c CD11b I-A CD11c CD11b 




3.2.3 Aortic DCs come from the bone marrow at steady state 
 
During homeostasis, non-lymphoid tissue DCs are known to be generated by 
hematopoietic cells from the bone marrow with the exception of Langerhans 
cells (LC) which can self-renew (Helft et al., 2010; Merad et al., 2002). To 
determine the origin of aortic DCs at steady state, CD45.2 WT mice were 
irradiated and re-constituted with congenic CD45.1 bone marrow cells. 18 
weeks after transplant, when the mice were 24 weeks old, both CD11b+ and 
CD103+ DC subsets in the aorta were mostly of donor CD45.1 origin (Figure 
3.3A and 3.3B). Thus, aortic DCs originate from the bone marrow at steady 
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Figure 3.3 Aortic DCs originate from the bone marrow at steady state.  
(A) CD45.1 donor WT total bone marrow cells were injected into irradiated 
congenic CD45.2 WT recipient mice at 6 weeks of age and aortic cell 
suspensions were analyzed by flow cytometry 18 weeks after the transplant. 
After gating for live singlet cells which are I-A+ CD11c+, CD11b+ (black) and 
CD103+ (white) DC subsets were further analyzed for their origin. (B) Bar 
graph showing percentage of CD11b+ and CD103+ DCs which comes from 
donor CD45.1+ cells. Data shown are representative of two independent 































3.2.4 Atherosclerosis-induced expansion of both CD11b+ and CD103+ 
DC subsets in apoE-/- mice 
 
There are two mouse models of atherosclerosis, apoE-/- and Ldlr-/-. In apoE-/- 
mice, atherosclerotic lesions develop spontaneously and development of 
disease is accelerated with feeding of high fat, rich cholesterol, diet. In 
contrast, atherosclerotic lesions only develop upon high fat feeding in the  
Ldlr-/- mice. Both models are widely used for studies in atherosclerosis. As 
mentioned previously, the study on DC subsets in atherosclerosis mainly 
focused on the Ldlr-/- mice. To determine if the same DC subsets exist in  
apoE-/- mice, flow cytometric analyses of aortic cell suspensions were 
performed.  
Consistent with a previous report (Galkina et al., 2006), increased numbers of 
CD45+ leukocytes  and DCs can be observed in apoE-/- mice compared to WT 
controls (Figure 3.4 and 3.5A).  Both CD11b+ and CD103+ DC subsets were 
found to be significantly increased as a percentage of CD45+ leukocytes and 
absolute numbers in the apoE-/- mice (Figure 3.5B and 3.5C). 
To determine the localization and assess the accumulation of DCs in aortic 
lesions during progression of atherosclerosis, mice were sacrificed at 10, 16 
and 24 weeks of age and sections of aortas were stained with I-A, CD11c and 
CD11b. Accumulation of DCs mainly occurred in the intima of aorta (Figure 
3.6). They were rarely detected in the adventitia. At 10 weeks of age, small 
foam cell atherosclerotic plaques can be found (Stary et al., 1994) with I-A+ 




CD11c+ CD11b+ DCs dominating the plaque area (Figure 3.6A). With 
increasing duration of high fat diet feeding, the atherosclerotic lesions became 
larger and the localization of CD11b+ DCs was altered. At 16 weeks of age, 
fatty streak lesions developed (Stary et al., 1994) and plaque CD11b+ DCs 
were found at the outermost layer of intima (Figure 3.6B). At 24 weeks of age, 
atherosclerotic plaques that form are usually fibroatheromatous plaques with 
necrotic core and fibrous caps (Stary et al., 1995; Whitman, 2004). At this 
stage, plaque CD11b+ DCs mainly localized on the top layer of fibrous 
plaques (Figure 3.6C) and the shoulder regions (Figure 3.6D).  
The localization of plaque CD11b+ DCs on the outermost layer of intima 
coupled with the observation that CD11b+ DCs were rarely found in the 
adventitia, indicated that these cells are unlikely to migrate from the 
ablumenal-lumenal direction (Randolph et al., 1998). Instead, they are formed 
from newly-formed cells from the circulation. Plaque CD11b+ DCs are also 
located in plaque shoulders which are sites predisposed to vulnerability and 
rupture in human atherosclerotic lesions (Finn et al., 2010), suggesting they 










                     
 
                       
 
                   
 
Figure 3.4. Atherosclerosis induced leukocyte infiltration and expansion 
of DCs in apoE-/- mice.    
Representative flow cytometric plots showing increased percentages of 
leukocytes (CD45+), DCs (I-A+ CD11c+) and CD11b+ DC subset in apoE-/- 
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Figure 3.5 Expansion of DCs in apoE-/- mice was due to accumulation of 
both CD11b+ and CD103+ DC subsets.  
(A) Bar graph showing percentage of I-A+ CD11c+ DCs in aortas of apoE-/-
(white) and WT mice (black). (B and C) Bar graphs showing percentages of 
CD11b+ and CD103+ DC subsets as a percentage of total CD45+ leukocytes 
and their absolute numbers in aortas of apoE-/- (white) and WT mice (black) 
respectively. Data shown are representative of at least 3 independent 
experiments (n = 2-3) per group. Student’s t test: *** p<0.001, **p<0.05, 












































































Figure 3.6. Accumulation of 
DCs occurred across disease 
progression.  
Sections were stained with I-A 
(white), CD11c (red), CD11b 
(green) and DAPI (blue) to 
identify DCs, particularly 
CD11b+ DCs. (A-D) 
Accumulation of I-A+ CD11c+ 
DCs can be seen across 
increasing weeks of high fat 
diet feeding. CD11b+ DCs 
(yellow arrows) are mostly 
localized in the intima. L: 
lumen; I: intima; M: media; 
Adv: adventitia; Sh: shoulder. 
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3.2.5 Atherosclerosis-induced expansion of DC subsets in Ldlr-/- mice 
 
As Ldlr-/- mice do not spontaneously develop atherosclerotic lesions in 
contrast to apoE-/- mice, the progression of disease is much slower in this 
model (Sjoland et al., 2000; Whitman, 2004). To obtain similar advanced 
plaques in a 24 week old apoE-/- mice (18 weeks of high fat diet), Ldlr-/- mice 
used in this study were placed on at least 24 weeks of high fat diet.  
Similar to apoE-/- mice, an accumulation of DCs (Figure 3.7A) was observed 
in Ldlr-/- mice. However, the accumulation of DCs in the Ldlr-/- mice 
(approximately 6%) was less severe compared to apoE-/- (approximately 15%), 
reflecting the differences in the two models. Contrary to a previous study 
(Choi et al., 2011) which reported an accumulation of both DC subsets in Ldlr-
/- mice,  only the CD11b+ DC subset was significantly increased (Figure 3.7B) 
in our study. The differences may be due to the duration of high fat diet 
feeding which was 16 weeks compared to 24 weeks in our study.  In terms of 
absolute numbers, there was a modest but not statistically significant increase 
in CD11b+ DCs (Figure 3.7C).  

































































Figure 3.7. The expansion of DCs in Ldlr-/- mice was due to an 
accumulation of the CD11b+ DC subset rather than the CD103+ DC 
subset.  
(A) Bar graph showing percentage of I-A+ CD11c+ DCs in aortas of Ldlr-/-
(shaded) and WT mice (black). (B and C) Bar graphs showing percentages of 
CD11b+ and CD103+ DC subsets as a percentage of total CD45+ leukocytes 
and their absolute numbers in whole aortas of Ldlr-/- (shaded) and WT mice 
(black). Data shown are representative of at least 3 independent experiments 
(n = 2-3) per group. Student’s t test: **p<0.05, *p<0.01. Error bars represent 
SEM.  
 






In conclusion, we demonstrated the existence of two DC subsets: CD11b+ and 
CD103+ in the normal murine aorta whose phenotypes and proportions are 
analogous to other non-lymphoid tissues. These DC subsets are found in 
atherosclerosis-susceptible areas of the aorta. At steady state, both DC subsets 
come from bone marrow precursors as shown in the bone marrow 
transplantation experiment. 
Under chronic inflammation conditions, such as atherosclerosis, studies have 
shown an accumulation of immune cells in plaque-laden areas. However, there 
are no studies available investigating the DC subsets in the apoE-/- mouse 
model of atherosclerosis. Our data indicated that when atherosclerotic plaques 
develop in the atherosclerotic apoE-/- mice, an expansion of both CD11b+ and 
CD103+ DC subsets is observed. Interestingly, the expansion is proportional 
such that the ratio of CD11b+ and CD103+ DC subsets remain unchanged 
(70% CD11b+:10% CD103+), implying that maintaining this distribution of 
DC subsets in the aorta is physiologically relevant.  
In contrast, when a parallel study was conducted on the Ldlr-/- mice, a less 
severe model of atherosclerosis, only the CD11b+ DCs were found to 
accumulate. Furthermore, the extent of accumulation of CD11b+ DCs in the 
Ldlr-/- mice is smaller compared to apoE-/- mice. This suggests that the extent 
of disease severity may determine the amount of CD11b+ DC accumulation 























Chapter 4 – Origin of DCs in atherosclerosis 
4.1  Introduction 
 
Under inflammatory conditions, monocytes are known to be precursors of 
DCs (Dominguez and Ardavin, 2010). Since the origin of the CD11b+ DC 
subset is not well-studied in atherosclerosis, we wanted to investigate whether 
the CD11b+ DC subset in the atherosclerotic aorta comes from monocytes.   




4.2  Results 
4.2.1 Expression of CD64 distinguished monocyte-derived DCs  
 
CD64, the high-affinity IgG receptor FcγRI in the mouse is largely expressed 
by myeloid cells involved in antigen presentation and processing such as 
macrophages and DCs (Tan et al., 2003). Interestingly, recent findings have 
shown that expression of CD64 is able to distinguish MoDCs from cDCs 
(Langlet et al., 2012; Plantinga et al., 2013) and is a good marker for 
monocyte-derived cells (Tamoutounour et al., 2012).  
When we stained for CD64 by flow cytometry, we detected an increased 
percentage of CD11b+ DCs expressing CD64 in the apoE-/- mice compared to 
WT controls (Figure 4.1). Moreover, CD103+ DCs (CD11b-) were CD64 
negative in both apoE-/- and WT mice, suggesting that monocytes did not 
differentiate into CD103+ DCs (Figure 4.1). 





           
 
Figure 4.1 Expression of CD64 revealed expanded monocyte-derived DC 
population in apoE-/- mice compared to WT controls.  
Dot plots show CD11b and CD64 expression by CD45+ I-A+ CD11c+ DCs. 
Representative plot of 2 independent experiments, n = 2 per group.










4.2.2 CD11b+ DC subset arises from monocytes 
 
To assess whether monocytes can give rise to CD11b+ DCs during 
atherosclerosis, we adoptively transferred CD45.1 WT murine bone marrow 
monocytes into 24 weeks old CD45.2 apoE-/- recipients. Bone marrow 
monocytes were isolated by negative selection and purity of bone marrow 
monocytes was found to be 80-90% (Figure 4.2A).  1 day after transfer, we 
could detect 2-3% of blood monocytes in these recipients that are of CD45.1 
donor origin (Figure 4.2B). 3 days after the transfer, the percentage of blood 
monocytes in the apoE-/- recipients dropped to less than 1% (Figure 4.2C), 
suggesting mobilization of these monocytes into peripheral tissues. 
Indeed, when we looked at the aorta of these apoE-/- recipients, approximately 
0.02% of cells in the aorta were from the donor. When we further looked at I-
A and CD11c expression of these cells, approximately 5-6% of these cells 
were I-A+ CD11c+ DC, while the majority of the cells remained IA- CD11c- 
monocytes. Of I-A+ CD11c+ DCs that were CD45.1, all were CD11b+ DCs, 
suggesting that monocytes definitely can differentiate into CD11b+ DCs under 
atherosclerotic conditions (Figure 4.2D). These monocyte-derived CD11b+ 
DCs were also all CD64 positive, further supporting CD64 as a good marker 
in detecting monocyte-derived cells. Since donor monocytes only give rise to 
CD11b+ DCs in vivo, it also implied that CD103+ DC subset (CD11b- CD24+) 
in the aorta do not originate from monocytes under inflammatory conditions.  
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Figure 4.2. CD11b+ DCs in the aorta were of monocyte origin.  
CD45.1 WT monocytes were injected into apoE-/- mice at 24 weeks of age. 
(A) Dot plots showing percentages of monocytes (CD115+ Ly6G-) before 
(left) and after (right) negative selection. (B) Dot plots showing percentages of 
blood monocytes (CD11b+ Low SSC, CD115+ F4/80+) that came from donor 
(CD45.1) and host (CD45.2) cells 1 day and (C) 3 days after adoptive transfer 
respectively with CD45.1 and CD45.2 WT controls.  (D) CD45.1 donor cells 
were identified in aortic cell suspension of apoE-/- mice recipients and I-A+ 
CD11c+ DCs were further analyzed for CD11b, CD64 and CD24 expression. 4 
aortas were pooled for this analysis. 
CD45.1+ 
I-A+ CD11c+ I-A+ CD11c+ 






Here, we show for the first time that CD64 expression is able to discriminate 
monocyte-derived cells in the murine aorta. Based on CD64 expression, there 
is an increasing amount of CD11b+ DCs that differentiated from monocytes 
during atherosclerosis, consistent with literature that monocytes are a source 
of DCs during inflammatory conditions (Shortman and Naik, 2007).  
We also provide evidence that monocytes adoptively transferred into apoE-/- 
recipients can differentiate into CD11b+ DCs in the aorta in vivo. In contrast, 
adoptively transferred monocytes were shown to up-regulate F4/80 and MHC 
class II and suggesting that monocytes have differentiated into macrophages 
(Swirski et al., 2007). Of note, during both homeostasis and inflammation, 
CD103+ DCs do not arise from monocytes as CD103+ DCs are derived mainly 
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Chapter 5 – Mechanism(s) of DC accumulation in atherosclerosis 
5.1 Introduction 
 
Although the accumulation of DCs in atherosclerotic mice has been reported 
since 2006, there is still a lack of information on the potential mechanisms that 
could cause this process. Several hypotheses have been put forward to explain 
this accumulation. We have previously shown that hypercholesterolemia 
affects the ability of DCs to migrate from the skin to draining lymph nodes in 
the apoE-/- mice (Angeli et al., 2004), suggesting that aortic DCs may likewise 
have impaired emigration from atherosclerotic plaques to draining lymph 
nodes. Besides impaired emigration, accumulation of DCs in atherosclerotic 
aorta may be due to increased retention of these cells (Llodra et al., 2004) and 
the failure to up-regulate CCR7 (Trogan et al., 2006) in dyslipidemic 
conditions, supporting prolonged inflammation. Another probable explanation 
is an increased DC proliferation in nascent atherosclerotic lesions due to 
increased GM-CSF (Zhu et al., 2009). Lastly, GM-CSF is also known to 
promote DC survival in non-lymphoid tissues at steady state (Greter et al., 
2012a) and this could account for the accumulation.  
To date, none of these findings narrow down the mechanisms of accumulation 
for specific DC subsets. Earlier, we have determined that both CD11b+ and 
CD103+ DCs accumulated in apoE-/- mice and only CD11b+ DCs are derived 
from monocytes, suggesting different mechanisms for the accumulation of 
these two subsets. Indeed, it has been shown in a recent study that aortic 
CD103+ DCs originate from Flt3-dependent DC precursors whereas CD11b+ 




DCs are Flt3-independent in Ldlr-/- mice (Choi et al., 2011). Herein, we sought 
to explore the potential mechanisms for the accumulation of CD11b+ DCs in 
apoE-/- mice.  




5.2  Results 
5.2.1  Monocytosis occurs in the blood and aorta of apoE-/- mice  
 
As seen from the adoptive transfer (Section 4.2.2), monocytes can give rise to 
CD11b+ DCs in apoE-/- mice and it is well known that monocytosis occurs in 
blood of these mice. We sought to verify in our model whether monocytosis 
possibly contributes to CD11b+ DC accumulation.  
Blood monocytes are defined as CD11b+ with low side scatter and typically 
express CD115 and F4/80 (Sunderkotter et al., 2004). They can be divided 
into 2 subpopulations: Gr-1 high and Gr-1 low (Geissmann et al., 2003) 
(Figure 5.1A).  In agreement with literature, an increase in total monocytes 
was observed in the apoE-/- mice compared to WT controls (Figure 5.1B). 
Moreover, as reported in recent studies (Swirski et al., 2007; Tacke et al., 
2007), we observed a preferential Gr-1hi monocytosis in the blood, leading to a 
reduction in Gr-1low monocytes in apoE-/- mice (Figure 5.1C).  
While blood monocytosis is recognized in apoE-/- mice, there were no reports 
on whether this occurs in the atherosclerotic plaques. In the same 
atherosclerotic animals in which we observed blood monocytosis and CD11b+ 
DC accumulation in aorta, we found that total monocytes (I-A- CD11c- 
CD11b+) were also increased in aorta (Figure 5.2A). When we looked further 
into monocyte subsets in the aorta, we discovered that the increase could only 
be attributed to Gr-1hi monocytes (Figure 5.2B and C). This increase was also 
reflected by higher absolute number of Gr-1hi monocytes in the aorta (Figure 
5.2D).  
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Figure 5.1. Monocytosis in the blood of apoE-/- mice.  
(A) Monocytes in the blood are analyzed by flow cytometry. Leukocytes are 
gated followed by CD11b+ cells with low side scatter and CD115 and F4/80. 
Monocyte subsets are distinguished by Gr-1 expression. (B) Bar graphs 
showing percentage of total monocytes, Gr-1hi and Gr-1low monocytes of apoE-
/- (white) and WT mice (black). These results are representative of at least 3 
independent experiments (n = 4-6) per group. Student’s t test: *** p<0.001, 






















































Figure 5.2. Monocytosis in the aorta of apoE-/- mice.  
(A) Bar graph showing percentages of CD11b+ cells that are I-A- CD11c-. (B 
and C) Bar graphs showing percentages of Gr-1hi and Gr-1low monocyte 
subsets and their proportions in total leukocytes (CD45+). (D) Bar graph 
showing absolute numbers of Gr-1hi and Gr-1low monocyte subsets. ApoE-/-: 
white bar; WT: black bar. Data shown are representative of the same 
independent experiments (n = 2-3) per group as shown in Figure 4.2. Student’s 
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5.2.2 Ezetimibe abolished blood monocytosis in the blood and aorta of 
apoE-/- mice simultaneously with CD11b+ DC expansion in aorta 
 
Although we have shown earlier that monocytosis in the blood and aorta 
occurred simultaneously with CD11b+ DC accumulation, there is no direct 
evidence that monocytosis plays a part in CD11b+ DC accumulation. To assess 
the relationship between monocytosis and CD11b+ DCs, we induced disease 
regression in apoE-/- mice by administering a cholesterol-lowering drug, 
Ezetimibe.  
Ezetimibe is a cholesterol absorption inhibitor and has been shown to reduce 
atherosclerotic plaques in apoE-/- mice (Davis et al., 2001). After Ezetimibe 
treatment, blood monocytosis was reduced in apoE-/- mice (Figure 5.3A). 
Furthermore, Gr-1hi monocytosis that was previously detected in apoE-/- mice 
was reversed and the proportion of monocyte subsets in treated apoE-/- mice 
became comparable to WT controls (Figure 5.3B). This effect was 
accompanied by a reduction in total monocytes in aorta (Figure 5.3C) of 
treated apoE-/- mice and was again attributed to a decrease in Gr-1hi monocytes 
(Figure 5.3D).   
Together with the reversal of monocytosis in treated apoE-/- mice, we detected 
a decrease in I-A+ CD11c+ DCs in the aorta (Figure 5.4A). Strikingly, there 
was a reduction in CD11b+ DC accumulation (Figure 5.4A) without any effect 
on CD103+ DCs in the treated apoE-/- mice. This was also evident by 
immunofluorescent staining (Figure 5.5). Hence, monocytosis may likely 
account for CD11b+ DC accumulation in atherosclerotic aorta. 



















Figure 5.3. Ezetimibe reversed monocytosis in the blood and aorta of 
apoE-/- mice.  
(A) Bar graphs showing percentages of total monocytes, (B) Gr-1hi and Gr-
1low monocytes in the blood of apoE-/- non-treated (white), apoE-/- treated 
(grey) and WT non-treated (black) mice. (C) Percentage of total monocytes in 
aorta is displayed. (D) Bar graphs showing percentages of Gr-1 hi and Gr-1 
low monocytes in the aorta as a proportion of total monocytes (top) and of 
CD45+ leukocytes (bottom) respectively. NT: non-treated; T: treated. Data 
shown are representative of 4 independent experiments (n = 2-3) per group. 
Student’s t test: *** p<0.001, **p<0.05, *p<0.01. Error bars represent SEM.
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Figure 5.4. Ezetimibe abrogated CD11b+ DC accumulation in the aorta of 
apoE-/- mice. 
(A) Bar graphs showing percentages of I-A+ CD11c+ DCs and (B) CD11b+ 
and CD103+ DC subsets respectively in aortas of apoE-/- non-treated (white), 
apoE-/- treated (grey) and WT non-treated (black) mice. NT: non-treated; T: 
treated. Data shown are representative of 4 independent experiments (n=2-3) 
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Figure 5.5. CD11b+ DCs are 
reduced together with plaque 
size after Ezetimibe. 
Immunofluorescence analysis 
showed abolishment of CD11b+ 
DC accumulation after 
Ezetimibe treatment. (A) Panel 
of images show staining of 
CD11b+ DCs (yellow arrows) 
in apoE-/- mice treated with 
vehicle. L: lumen; I: intima; M: 
media; Adv: adventitia. 
Magnification 100x. Scale bar 
represents 50µm. (B) ApoE-/- 
mice treated with Ezetimibe for 
12 weeks have reduced plaque 
size and abolishment of 
CD11b+ DC accumulation.  L: 
lumen; I: intima; M: media; 
Adv: adventitia. Magnification 
100x. Scale bar represents 
 
 










5.2.3 Increase in bone marrow precursors does not account for CD11b+ 
DC accumulation   
 
Leukocytosis has been linked with proliferation and expansion of HSPCs in 
apoE-/- mice (Murphy et al., 2011). Therefore, we wondered whether DC 
precursors in the bone marrow are likewise expanded and eventually may 
account for CD11b+ DC accumulation in the aorta during atherosclerosis.  
In the bone marrow, there are two DC precursors: MDP and CDP. MDP gives 
rise to monocytes and CDP while CDP gives rise to pre-DCs. Both are known 
to differentiate into CD11b+ and CD103+ DC subsets in non-lymphoid tissues 
(Auffray et al., 2009a; Ginhoux et al., 2009). To define MDP and CDP in the 
bone marrow, mature hematopoietic cells which are lineage positive are 
excluded. Thereafter, Flt3+ CD11c- CD115+ and CD11b- cells were gated and 
analyzed for c-kit expression (Figure 5.6A) (Fogg et al., 2006; Onai et al., 
2007) . MDPs are c-kithi whereas CDPs are c-kitlow. Comparing apoE-/- mice to 
WT controls, there were no significant differences in MDP and CDP in the 
bone marrow (Figure 5.6B), ruling out the possibility that DC precursors in the 
bone marrow contributed to CD11b+ DC accumulation in the aorta.  
Given that monocytosis occurs in peripheral blood of apoE-/- mice (Section 
5.2.1), we also investigated whether bone marrow monocytes were expanded 
in apoE-/- mice. Interestingly, we did not detect any significant differences in 
total monocytes and monocyte subsets (Figure 5.6C). This is in contrast to an 
earlier study (Swirski et al., 2007) whereby the authors have observed an 
increase in bone marrow monocytes in apoE-/- mice over the duration of high 




fat diet feeding. However, this study did not compare bone marrow monocytes 
to WT controls, explaining the differences in our observations.  
In conclusion, bone marrow precursors: MDPs, CDPs and monocytes were not 
expanded in apoE-/- mice and are unlikely to provide for CD11b+ DC 
accumulation in the aorta. Also, since bone marrow monocytes are not 
expanded but peripheral blood monocytosis was observed indicated that there 
are factors in the periphery that encourage the development of monocytosis in 
the blood (Swirski et al., 2007). Otherwise, expansion of bone marrow 
monocytes might be occurring at earlier stages of atherosclerosis at 15-16 
weeks of age as observed in this study (Combadiere et al., 2008), thereby 
giving rise to blood monocytosis in apoE-/- mice.  
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Figure 5.6. Bone marrow DC progenitors and monocytes do not 
contribute to DC accumulation in the apoE-/- mice.  
(A) Gating strategy for DC progenitors, MDP and CDP is shown here. After 
selecting for live, aqua negative and singlet cells, lineage (lin) negative cells 
which are cells negative for B220, CD3, CD19, Gr-1, Ter-119, NK1.1 and 
Sca-1 are chosen. These cells are further gated based on CD11c, CD115, 
CD11b and Flt-3 expression. MDPs were c-kithi and CDPs were c-kitlow/int. (B) 
Bar graph shows percentage of MDPs and CDPs in the bone marrow. ApoE-/-: 
white bar; WT: black bar (C) Bar graph shows percentage of monocytes and 
monocyte subsets: Gr-1hi and Gr-1low. ApoE-/-: white bar; WT: black bar. Data 
shown here are from at least 3 independent experiments with n = 3-6 mice per 





































5.2.4 Extramedullary hematopoiesis does not play a role in CD11b+ DC 
accumulation 
 
Emergency hematopoiesis has been known to be activated under inflammation 
and infection settings (Takizawa et al., 2012). In an earlier study (Swirski et 
al., 2009), the spleen has been identified to serve as a monocyte reservoir in 
myocardial infarction. This process known as extramedullary monocytopoiesis 
can sustain monocyte recruitment into infracted hearts, allowing resolution of 
inflammation (Leuschner et al., 2012). A recent study (Robbins et al., 2012) 
revealed that such a process occurs in apoE-/- mice and supplies monocytes to 
atherosclerotic lesions. Hence, we set out to determine whether this is also 
observed in our model.  
Contrary to published reports, we do not observe any significant differences in 
total monocytes and monocyte subsets (Figure 5.7) between apoE-/- and WT 
control mice, that could account for CD11b+ DC accumulation in the aorta of 
apoE-/- mice. In the study that reported extramedullary hematopoiesis in  
apoE-/- mice, it was detected over weeks of high fat feeding and did not 
compare with age-matched WT control mice. In addition, the apoE-/- mice 
used were much older and on 30 weeks of high fat diet compared to 18 weeks 
of high fat diet in our experiments.   










Figure 5.7. Extramedullary hematopoiesis does not contribute to DC 
accumulation in apoE-/- mice.  
Splenic monocytes are defined as CD11b+ cells with low side scatter, CD115+ 
and F4/80 low. Bar graphs show percentage of total monocytes (left) and 
monocyte subsets (right) in spleens of apoE-/- (white bar) and WT controls 
(black bar). Data shown here are from 3 independent experiments with n = 4-5 





































5.2.5    CD11b+ DCs proliferate in the aorta  
 
Aside from increased precursors such as monocytes in the blood, one could 
also think that the expansion of DCs could occur through proliferation. In fact, 
during homeostasis, cDCs are known to replicate in situ (Diao et al., 2006) and 
non-lymphoid tissue DC subsets can proliferate in vivo (Ginhoux et al., 2009). 
Owing to these observations, a recent study showed that expansion of DCs in 
aeroallergen-induced airway inflammation was due to local proliferation of 
these cells instead of cell recruitment (Veres et al., 2013). In atherosclerotic 
Ldlr-/- mice, an intimal DC proliferation was demonstrated to contribute to the 
initiation of disease, although these DCs were resident 33D1+ CD11b- DCs 
(Zhu et al., 2009). In this study, by comparing the kinetics of proliferation of 
blood monocytes and aortic DCs together with blocking monocyte 
recruitment, they have shown that aortic DCs proliferated independently of 
monocyte recruitment.  
To study whether the expansion of CD11b+ DCs in atherosclerotic aorta was a 
result of local proliferation, a thymidine analog, EdU was injected into the 
mice. By performing a similar kinetic experiment in blood and aorta as 
described by Zhu et al., (Zhu et al., 2009), we observed minimal proliferation 
of CD11b+ DCs (approximately 1%) at 2 hours post-EdU injection when 
blood monocytes were not proliferating (data not shown). 12 hours after 
injecting EdU, consistent with literature (Swirski et al., 2007; Zhu et al., 
2009), blood monocytes in apoE-/- mice were proliferating more than in WT 
mice (Figure 5.8), accounting for monocytosis in apoE-/- mice. In the aorta, we 
found that approximately 5% of CD11b+ DCs were proliferating (EdU+) in 




apoE-/- mice (Figure 5.9). However, there was no difference in the percentage 
of proliferating CD11b+ DCs between apoE-/- and WT control mice, indicating 
that local CD11b+ DC proliferation in the aorta is unlikely accounting for the 
CD11b+ DC accumulation in atherosclerosis. Notably, the majority of CD11b+ 
DCs in the aorta were also non-proliferating cells (Figure 5.9). 





   
Figure 5.8. Increased proliferation of blood monocytes contributed to monocytosis in apoE-/- mice.  
Dot plots show proliferating monocytes (CD115+ EdU+) in apoE-/- (top row) and WT control (bottom row) mice measured 12 hours after a single 















Figure 5.9. CD11b+ DC subset proliferated locally in the aorta. 
After a single dose of EdU injection, mice were sacrificed 12 hours later and 
proliferation was measured by flow cytometry. Dot plots showing proliferation 
of CD11b+ DCs (I-A+ CD11c+) measured by percentage of EdU+ DCs in  
apoE-/- (top panel) and WT (bottom panel) mice. Data shown here is 
representative of 3 independent experiments, n = 2-3 per group.  




5.2.6 GM-CSF, a DC growth factor, is up-regulated and produced 
locally in atherosclerotic aorta 
 
Classically, Flt3L and GM-CSF are DC growth factors that have been used to 
generate DC in cultures (Shortman and Naik, 2007). Flt3L is an essential 
factor for cDC and pDC development at steady state as Flt3L-/- mice have low 
numbers of DCs (McKenna et al., 2000). For non-lymphoid tissue DCs, Flt3 
plays a more important role in the development of CD103+ DCs in skin, lung, 
liver, kidney, (Ginhoux et al., 2009), pancreatic islet (Yin et al., 2012) and 
aorta (Choi et al., 2011).  
In contrast, GM-CSF is thought to be a growth factor for DCs only under 
inflammatory conditions because development of lymphoid tissue DCs occur 
normally in mice deficient in GM-CSF or its receptor (Vremec et al., 1997). 
Importantly, GM-CSF levels are low under homeostatic conditions but 
increase during inflammation (Cheers et al., 1988; Hamilton, 2002). Yet, a 
recent report revealed that the absence of GM-CSF disrupts non-lymphoid 
tissue DC homeostasis particularly CD103+ DCs while CD11b+ DCs were 
unaffected except for CD103+ CD11b+ DCs in the lamina propia (Greter et al., 
2012a). 
Lastly, M-CSF (also known as CSF-1) is a growth factor for macrophage 
cultures but DCs also express the receptor for M-CSF and M-CSF deficient 
op/op mice are known to exhibit reduced pDCs and cDCs (MacDonald et al., 
2005). Furthermore, another group has shown the ability of M-CSF to 
generate pDCs and cDCs both in vitro and in vivo independently of Flt3 




(Fancke et al., 2008). IL-34, an alternative ligand for the M-CSF receptor 
(Chihara et al., 2010), has also been shown to be essential to the development 
of LCs, a unique DC subset in the skin (Greter et al., 2012b; Wang et al., 
2012). 
We hypothesized that DC growth factors might be elevated and contribute to 
the expansion of CD11b+ DCs seen in apoE-/- mice.  We went on to examine 
the mRNA expression of these growth factors in the aorta. Although the 
expression of Flt3L and M-CSF are increased in apoE-/- aorta, it is not 
statistically significant compared to WT aorta. Hence, among the four growth 
factors discussed above, only GM-CSF was significantly up-regulated (fold 
change ≈ 6.6) in apoE-/- aorta compared to WT aorta (Figure 5.10A). 
Likewise, GM-CSF was elevated in Ldlr-/- mice (fold change ≈ 4.8) (Figure 
5.10B). Although GM-CSF was reported to preferentially increase in the 
spleen for extramedullary hematopoiesis to occur (Robbins et al., 2012), we 
did not detect this in our model (Figure 5.10C).  
We also validated the increase of GM-CSF levels in atherosclerotic aorta by 
ELISA assay and found a 3-fold increase in GM-CSF protein levels (Figure 
5.10D). There was no difference in GM-CSF levels in aortic draining lymph 
nodes (iliac lymph nodes) (Figure 5.10D). Furthermore, though circulating 
GM-CSF levels have been reported to increase in response to LPS-induced 
inflammation (Sheridan and Metcalf, 1972), both serum and plasma GM-CSF 
levels were undetectable by ELISA (data not shown).  
Our findings indicated that during atherosclerosis, GM-CSF expression is 
increased and restricted to the aorta as it is not found in the spleen, circulation 




and draining lymph nodes. This suggests that the production of GM-CSF in 
the aorta in apoE-/- mice may be involved in the expansion of CD11b+ DCs in 
the aorta. Comparing the difference in fold increase of GM-CSF between 
apoE-/- (fold change ≈ 6.6) and Ldlr-/- (fold change ≈ 4.8) with the percentage 
of CD11b+ DC expansion in these models (apoE-/-: 2.04 fold; Ldlr-/-: 1.48 fold) 
also imply that the amount of GM-CSF present in the aorta determined the 
extent of CD11b+ DC accumulation.  
 
 


































































































































































































Figure 5.10. GM-CSF is the sole DC growth factor up-regulated in 
atherosclerotic plaques and its production is localized in the aorta.  
(A) mRNA expression of GM-CSF, Flt3L, M-CSF and IL-34 in aorta of apoE-
/- and WT mice. Data shown from one experiment, n = 5 per group. (B) 
mRNA expression of GM-CSF in aorta of Ldlr-/- (shaded bar) and WT mice. 
Data shown from one experiment, n = 5 per group. (C) Splenic GM-CSF 
mRNA expression between apoE-/- and WT mice. Data collected from one 
experiment, n = 5 per group. (D) GM-CSF protein expression was measured 
by ELISA in aorta and associated draining lymph node (iliac lymph node) in 
apoE-/- and WT mice. Data shown was from one experiment, n = 6 per group 
for aorta and n = 3 per group for iliac lymph node. ApoE-/-: white bar; WT: 











































5.2.7 Production of GM-CSF is decreased along with CD11b+ DC 
accumulation in Ezetimibe-induced disease regression 
 
Considering that elevated GM-CSF levels may be responsible for CD11b+ DC 
accumulation in the aorta, we hypothesized that GM-CSF levels will be 
similarly affected as CD11b+ DC accumulation in a disease regression model 
(Section 5.2.2). Thus, we assessed the amount of GM-CSF production in mice 
treated with Ezetimibe.  
We found that Ezetimibe treatment induced a down-regulation of GM-CSF 
mRNA expression in apoE-/- mice (Figure 5.11A) and this drop was also 
significantly reflected at protein level (Figure 5.11B). 











Figure 5.11. Ezetimibe treatment reduced production of GM-CSF.  
(A)  mRNA expression of GM-CSF in aorta. Data shown consists of n = 5 
mice per group. (B) Protein expression of GM-CSF in aorta. Data shown from 
one experiment, n = 5-6 mice per group. ApoE-/- NT: white bar; ApoE-/- T: 
grey bar. WT NT: black bar. NT: non-treated; T: treated. Student’s t test: **** 


























































Earlier reports have established few theories behind the accumulation of DCs 
in atherosclerosis. Thus far, we have extended investigation into specifically 
CD11b+ DCs. There are three possible mechanistic explanations for the 
expansion of CD11b+ DCs. They are: increased precursors, increased in situ 
proliferation or increased differentiation and survival by growth factors. 
We have clearly demonstrated that bone marrow precursors and 
extramedullary hematopoiesis do not play a role in the expansion of CD11b+ 
DC in atherosclerotic aorta. Based on our earlier finding that monocytes give 
rise to CD11b+ DCs (Chapter 4), we verified that monocytosis occurred in our 
model as shown by others. We confirmed that monocytosis is essential to the 
expansion of CD11b+ DCs by reversing the process of hypercholesterolemia 
with a cholesterol-lowering drug, Ezetimibe, which eliminated monocytosis 
and CD11b+ DC expansion in apoE-/- mice.  
Though we showed that CD11b+ DCs can proliferate in situ in the aorta, there 
was no difference in the proliferative ability of CD11b+ DCs between apoE-/- 
and WT mice. More importantly, most of the CD11b+ DCs in the aorta are 
actually non-proliferating cells, strongly suggesting that proliferation is not a 
major mechanism for CD11b+ DC expansion.   
Lastly, we showed that GM-CSF is the only DC poietin that is highly up-
regulated and localized in the atherosclerotic aorta. We further confirmed that 
elevated GM-CSF levels accounted for CD11b+ DC accumulation by 




Ezetimibe treatment. The decrease of hypercholesterolemia by Ezetimibe 
treatment restored GM-CSF levels closer to homeostatic conditions and was 







GM-CSF: a DC poietin




Chapter 6 – GM-CSF: a DC poietin 
6.1 Introduction 
 
Previously we demonstrated that elevated GM-CSF levels in the aorta 
accounted in part for CD11b+ DC expansion in atherosclerosis. GM-CSF is a 
well-recognized cytokine for promoting DC differentiation and survival in 
vitro (Inaba et al., 1992; Ni and O'Neill, 2001). Yet, recent evidence showed 
that GM-CSF is not just a simple DC poietin.  
GM-CSF and Flt3L are known to preferentially expand different DC subsets 
(Daro et al., 2000; Parajuli et al., 2001). DCs derived from GM-CSF resemble 
closely to inflammatory TipDCs whereas those derived from Flt3L represent 
steady state resident DCs (Xu et al., 2007). The presence of GM-CSF is also 
sufficient to divert committed Flt3L-derived DCs (pDCs and CD8+ Sirpα- 
DCs) into GM-CSF derived DCs (CD8- Sirpα+ DCs) (Zhan et al., 2012) and to 
prevent differentiation into DC-like regulatory macrophages (Diao et al., 
2012).  
Besides influencing the developmental outcome of DCs, an early study on a 
GM-CSF producing tumor cell vaccine implied an ability of GM-CSF to 
recruit DCs at vaccination sites through local release of MIP-1α (Kielian et al., 
1999). GM-CSF was also found to be required for DC recruitment and 
survival in vivo as part of host response against an enteric bacterial pathogen 
infection (Hirata et al., 2010). 




The role of GM-CSF is not well-studied in atherosclerosis. It has been proven 
that GM-CSF is pro-atherogenic in Ldlr-/- mice by promoting a DC 
accumulation (Shaposhnik et al., 2007) and intimal DC proliferation (Zhu et 
al., 2009). Conversely, the function of GM-CSF is less clear in the apoE-/- 
mice. While GM-CSF deficiency in apoE-/- mice was shown to increase 
atherosclerosis, indicating an anti-atherogenic role for GM-CSF (Ditiatkovski 
et al., 2006), supplementing GM-CSF to apoE-/- mice exacerbated disease, 
implying that GM-CSF is pro-atherogenic in this study (Haghighat et al., 
2007).  
Though we demonstrated that GM-CSF is required for CD11b+ expansion in 
Apoe-/- mice, the identity of cells that are responsive to GM-CSF signaling and 
the source of GM-CSF are still unknown. Consequently, we decided to 
examine the expression of GM-CSF receptors and determine the source of 
GM-CSF in atherosclerotic plaques.  





6.2.1 GM-CSF Receptors are highly up-regulated in atherosclerotic 
aorta 
 
GM-CSF receptor is a heterodimer made up of two subunits: α ligand-binding 
subunit and β common signaling subunit. While the α subunit is cytokine-
specific, the GM-CSF βc subunit is shared with other cytokines, IL-3 and IL-
5. In the mouse, IL-3 has an additional β chain subunit, βIL-3 (GM-CSF 
receptor β2) which can bind to IL-3Rα in the absence of the common β 
subunit for IL-3 signaling to occur (Robb et al., 1995).  
We first assessed the mRNA expression of GM-CSF receptors and observed 
that both α (fold change ≈ 7) (Figure 6.1A) and βc (fold change ≈ 4) (Figure 
6.1B) subunits were up-regulated in apoE-/- mice compared to WT controls. 
Since the βc subunit is common to both the IL-3 and IL-5 receptors, to exclude 
a contribution of IL-3 and IL-5, we investigated the cytokine-specific α 
subunits for both receptors. There was no significant difference in the IL-5 
receptor α subunit (Figure 6.1C) between apoE-/- and WT mice. However, 
there was an increase in IL-3 receptor α subunit (fold change ≈ 2) (Figure 
6.1D) and βIL-3 (fold change ≈ 22) (Figure 6.1E), implying that elevated 
amounts of IL-3 receptor complexes are formed in atherosclerosis.  
Given that IL-3 together with GM-CSF can stimulate emergency 
hematopoiesis (Robbins et al., 2012) and IL-3 can generate myeloid DCs 
independently of GM-CSF (Baumeister et al., 2003), we assessed the 




expression of this cytokine in the aorta. Surprisingly, there was no difference 
in IL-3 expression (Figure 6.1F) between apoE-/- and WT mice.  












































































































































































Figure 6.1. Both α and β subunit of GM-CSF receptor are elevated in 
atherosclerotic aorta.  
(A and B) mRNA expression of α and βc subunits of GM-CSF receptor in 
aorta. (C) mRNA expression of IL-5 receptor α subunit in aorta. (D) mRNA 
expression of IL-3 receptor α subunit in aorta. (E) mRNA expression of 
additional IL-3 β subunit, βIL-3 (GM-CSF receptor β2) in aorta. (F) mRNA 
expression of IL-3 in aorta. ApoE-/-: white bars; WT: black bars. Data 
collected from one experiment, n = 5 per group. Student’s t test: **p<0.05, 







































































6.2.2 Circulating monocytes expressed both subunits of GM-CSF 
receptor with βc subunit being up-regulated in atherosclerosis  
 
Earlier we have shown that GM-CSF receptors were elevated in 
atherosclerosis without identifying the cells that express them. Expression of α 
subunit of GM-CSF receptor (GMRα) is mainly detected on myeloid cells and 
is highest in monocytes (Rosas et al., 2007). Thus far, expression of βc subunit 
(CD131) in mouse has been reported for neutrophils (Robb et al., 1995) and 
DC subsets (Greter et al., 2012a). However, the receptor subunits are always 
co-expressed on leukocytes (Hercus et al., 2009). Here, we sought to 
investigate the cells which express GM-CSF receptors by flow cytometry. 
Circulating monocytes expressed both GMRα and CD131 with Gr-1hi 
monocytes expressing higher levels than Gr-1low monocytes (Figure 6.2A). In 
addition, monocytes in apoE-/- mice expressed higher levels of CD131 than 
WT mice (Figure 6.2B), while there is no difference in GMRα levels. To 
determine whether the expression level of CD131 is up-regulated due to 
atherosclerosis in apoE-/- mice, we further examined the expression level in 
apoE-/- mice treated with Ezetimibe. Indeed, we found that expression of 
CD131 on circulating monocytes is reduced in apoE-/- mice treated with 
Ezetimibe (Figure 6.2C), suggesting that expression of CD131 is likely 
regulated by inflammation. 



























Figure 6.2. Circulating monocytes express both subunits of GM-CSF receptor with βc subunit being inflammation-dependent.  
(A) Histograms show expression of GMRα (top) and CD131 (bottom) on circulating monocytes of WT mice. Numbers in the plot indicate 
geometric mean fluorescence intensity (GMFI). (B) Comparison of GMRα (top) and CD131 (bottom) expression level between apoE-/- and WT 
mice. Numbers in the plot represent GMFI. (C) Comparison of CD131 expression level in apoE-/- mice treated with Ezetimibe (ApoE-/- T), apoE-
/- treated with vehicle (ApoE-/- NT) and WT mice. Numbers beside the histograms indicate GMFI. Data shown are representative of 2 
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6.2.3 CD11b+ DCs in the aorta expressed both subunits of GM-CSF 
receptors and βc subunit was increased in apoE-/- mice 
 
Since we showed that GM-CSF contributes to CD11b+ DC expansion in aorta, 
we hypothesized that CD11b+ DCs express the receptors to be responsive to 
GM-CSF signaling. Consistent with a recent study (Greter et al., 2012a), 
CD11b+ DCs expressed both GM-CSF receptors at steady state. Moreover, in 
the aorta, only DCs expressed GMRα with CD11b+ DCs expressing a higher 
level of the receptor than CD103+ DCs (Figure 6.3A). In contrast, expression 
of CD131 is not restricted to DCs in the aorta but was also detected on 
monocytes (Figure 6.3B). However, the Gr-1hi monocytes expressed negligible 
or low level of CD131 while Gr-llow monocytes expressed more.  
As we have seen inflammation regulates the expression of CD131 on 
circulating monocytes (Section 6.2.2), we also investigated whether this is true 
for the aorta. Indeed, preliminary results show that expression of CD131 on 
CD11b+ DCs is higher in apoE-/- mice compared to WT controls (Figure 6.4). 
Other than CD11b+ DCs, the expression of CD131 remains unchanged 
between apoE-/- and WT mice for the other populations in the aorta such as 
CD103+ DCs, monocytes and monocyte-derived cells (data not shown).  
Functional GM-CSF receptors require both the α and β subunits. In the aorta, 
only the DCs possess both subunits, suggesting that they are the only ones 
responsive to GM-CSF signaling. Importantly, the CD11b+ DCs up-regulate 
the signaling β subunit during atherosclerosis, implying that they have a 
higher capacity to respond to GM-CSF. 








Figure 6.3. CD11b+ DCs possessed GM-CSF receptor at steady state. 
(A) Histograms show GMRα expression in CD11b+ and CD103+ DCs in aorta 
of WT mice.      Isotype;     GMRα. (B) Histograms depict CD131 expression 
on DC and monocyte subsets in aorta of WT mice.     Isotype;      CD131. 
Numbers shown inside histograms represent GMFI. Data shown are from n > 
3. 





Figure 6.4. CD11b+ DCs expressed higher level of CD131 in 
atherosclerotic aorta.  
Histogram comparing expression level of CD131 on CD11b+ DCs between 
apoE-/- and WT mice. Geometric mean fluorescence intensity (GMFI) is 








 6.2.4 Sources of GM-CSF 
 
GM-CSF can be produced by a myriad of cells such as T cells, macrophages, 
fibroblasts, endothelial cells and tumor cells (Shi et al., 2006). In 
atherosclerosis, GM-CSF can be produced by vascular smooth muscle cells 
(Plenz et al., 1997) and expression can be induced in endothelial cells 
(Rajavashisth et al., 1990) by modified lipoproteins. A recent study revealed 
GM-CSF as a CD8+ T cell factor important for formation of potent effector 
DCs (Min et al., 2010). Based on these studies, we set out to evaluate the cells 
producing GM-CSF in atherosclerotic plaques with a focus on T cells.  
Indeed, we could find CD3+ T cells that produce GM-CSF (Figure 6.5). 
Interestingly, some CD11b+ cells were found to colocalize with GM-CSF 
staining. In order to identify whether GM-CSF producing CD11b+ cells are 
DCs, we stained serial sections with markers of DCs and looked at their 
localization. We saw that the area where CD11b+ DCs were located, positive 
GM-CSF staining could be found in the subsequent section (Figure 6.6).  
A preliminary study on aorta by flow cytometry confirmed that CD11b+ DCs, 
CD4+ and CD8+ T cells produce GM-CSF (Figure 6.7). GM-CSF production 
could also be detected on other immune cells such as macrophages and 
monocytes (data not shown).  
 
 
    




Figure 6.5. CD3 T cells and 
CD11b+ cells are sources of 
GM-CSF in atherosclerotic 
plaque.  
Immunofluorescence staining 
indicated CD3 T cells 
(triangle) and CD11b+ cells 
(yellow arrow) produce GM-
CSF.  L: lumen; I: intima; M: 
media; Adv: adventitia. 
Magnification 200x. Scale bar 
represents 50µm.  
 




Figure 6.6. Serial sections 
showed CD11b+ cells are 
I-A+ CD11c+ DCs 
producing GM-CSF.  
Colocalization of GM-CSF 
and CD11b is indicated by 
yellow arrows. CD3 T cells 
producing GM-CSF are 
present inside the plaque 
and outside in the adventitia 
(white arrows). L: lumen; I: 
intima; M: media; Adv: 
adventitia. Magnification 
200x. Scale bar represents 
50µm.  
 




Figure 6.7. CD11b+ DCs, 
CD8+ and CD4+ T cells 
produced GM-CSF in the 
atherosclerotic aorta. 
Monensin (1x) was added to 
aorta during digestion to block 
cytokine exocytosis. 
Thereafter, intracellular GM-
CSF staining was performed 
directly ex vivo on aortic cells 
without re-stimulation. Dot 
plot show intracellular GM-
CSF production (top) in 
CD11b+ DCs, CD8+ and CD4+ 
T cells in apoE-/- aorta. 
Bottom: FMO control. 
Fluorescence minus one 
(FMO) control was set up by 
staining for every antibody in 
the panel except for GM-CSF.   
Data shown is from a group of 
   




6.2.5 Neutralizing GM-CSF diminished monocytosis and CD11b+ DC 
accumulation  
 
Since CD11b+ DCs possess GM-CSF receptor (Section 6.2.3), produce GM-
CSF themselves (Section 6.2.4) and are likely to expand under the influence of 
GM-CSF (Section 5.2.7), we postulated that neutralizing GM-CSF by 
intraperitoneal injection into apoE-/- mice should lower their expansion.  
Preliminary results showed that blocking GM-CSF significantly reduced 
monocytosis in the blood (Figure 6.8A). This decrease was a result of a drop 
in Gr-1hi monocytosis which was associated with a partial increase in the 
percentage of Gr-1low monocytes (Figure 6.8B). Despite the reduction of blood 
monocytosis, monocytes in the aorta were unaffected by the treatment. 
Decreased blood monocytosis was accompanied by a decline in CD11b+ DC 
accumulation in aorta of apoE-/- mice treated with anti-GM-CSF antibody 
(Figure 6.8C), showing that aortic GM-CSF levels regulate the expansion of 
CD11b+ DC in apoE-/- mice. 


















Figure 6.8. Blocking GM-CSF reduced blood monocytosis and CD11b+ 
DC expansion in the aorta.  
Anti-GM-CSF antibody was given by intraperitoneal injection consecutively 
for 4 days and mice were sacrificed on day 5. (A and B) Bar graphs depict 
percentage of monocytes and their subsets in the blood of apoE-/- NT and 
apoE-/- T respectively on day 5. Data shown consists of n = 6 mice per group. 
(C) Bar graph showing percentages of CD11b+ DCs in terms of total CD45+ 
leukocytes in apoE-/- NT and apoE-/- T mice after 4 days of anti-GM-CSF 
antibody administration. Data shown are from 2 independent experiments with 
n = 2-3 per group. NT: non-treated (white bar); T: treated (grey bar). Student’s 





























































6.2.6 BMDCs as model for CD11b+ DCs 
 
As seen in vivo, CD11b+ DCs expressed GM-CSF receptors and produce GM-
CSF themselves. The evidence of this autocrine loop implied that CD11b+ 
DCs may support their own survival. To test this hypothesis and to find an 
equivalent of CD11b+ DCs for in vitro studies, we freshly isolated bone 
marrow cells and cultured them with GM-CSF for 6 days (Inaba et al., 1992) 
before stimulation with LPS to mimick inflammatory conditions.  
After stimulation with LPS, approximately 30-40% of DCs were I-Ahi 
CD11chi. Of this population, all were CD11b+ and CD24hi. Most BMDCs were 
also Gr-1low and F4/80+ with intermediate levels of CD115 (Figure 6.9A). 
About 60% of BMDCs were also CD64+ (Figure 6.9B). These BMDCs were 
markedly similar to aortic CD11b+ DCs with the exception that CD24 
expression on CD11b+ DCs in the aorta ranged from low to high. Akin to 
aortic CD11b+ DCs, they expressed Sirpα and CD131 and these markers were 
up-regulated after stimulation with LPS (Figure 6.9C). Therefore, BMDCs 
cultured with GM-CSF resemble aortic CD11b+ DCs for in vitro studies.  

















Figure 6.9. BMDCs cultured with GM-CSF are reminiscent of CD11b+ 
DCs in aorta.  
BMDCs derived from a culture of bone marrow cells with GM-CSF after 6 
days were stimulated with 1µg/ml LPS. (A) Expression of I-A, CD11c, 
CD115, CD11b, F4/80, Gr-1 and CD24 was analyzed. (B) Dot plots show 
CD64 expression (right) on BMDCs against isotype control (left). (C) 
Histograms show expression of CD131 (left) and Sirpα (right) between 









6.2.7 GM-CSF secretion by BMDCs promote their own survival 
 
To examine whether autocrine production of GM-CSF by CD11b+ DCs 
supports their own survival, we isolated and cultured BMDCs as before. 
However, on day 6 of culture, we deprived the cells of serum and exogenous 
GM-CSF to investigate the effects on their survival. For this, culture 
supernatants were collected for detection of GM-CSF protein by ELISA. 
Simultaneously, the cells were stained with Annexin and PI to assess their 
survival by flow cytometry. 
Interestingly, endogenous secretion of GM-CSF by BMDCs increased over 
time (Figure 6.10A). The production of GM-CSF was increased slightly with 
LPS stimulation. Concurrent with this increase in GM-CSF production, we 
detected a decrease in late apoptotic (Annexin+ PI+) cells over time (Figure 
6.10B).












Figure 6.10. Secretion of GM-CSF coincides with survival of BMDCs.  
BMDCs were deprived of serum and growth factor, GM-CSF on day 6 and 
were left unstimulated or stimulated with LPS for 24, 48 and 72 hours. (A) 
Culture supernatant was collected and assayed for GM-CSF protein 
concentration by ELISA. (B) Cell survival of BMDCs was analyzed by 










































Here, we showed that both the α and β subunits of the GM-CSF receptor were 
also increased at mRNA level with the ligand, GM-CSF. Although GM-CSF 
receptors are known to be expressed on monocytes, we demonstrated for the 
first time that circulating monocytes in apoE-/- mice expressed higher levels of 
CD131. This expression was also regulated by the extent of inflammation. 
Moreover, only DCs in the aorta possess both subunits, with CD11b+ DCs 
expressing higher levels of CD131, indicative of a higher ability to respond to 
GM-CSF.  
We have also found T cells and DCs to be the source of GM-CSF in 
atherosclerotic plaques. It is not known that DCs produce GM-CSF 
themselves and this may be unique to the aorta. Blocking GM-CSF directly 
with a neutralizing antibody resulted in a partial reduction in monocytosis and 
CD11b+ DC expansion. This reinforced the fact that increased GM-CSF in the 
aorta participate in CD11b+ DC expansion. 
Since CD11b+ DCs expressed GM-CSF receptor and produced GM-CSF 
themselves, we hypothesize that this autocrine loop affects their survival. We 
use BMDCs as models of CD11b+ DCs and observed that they produce 
increasing amounts of GM-CSF over time after serum-starvation and 
withdrawal of exogenous GM-CSF. This increase in production coincided 










Function of CD11b+ DCs




Chapter 7 – Function of CD11b+ DCs 
7.1 Introduction 
 
During inflammation, monocyte-derived DCs produced pro-inflammatory 
mediators such as TNF-α and iNOS that may contribute to disease 
pathogenesis (Chong et al., 2011; Serbina et al., 2003).We wondered if 
monocyte-derived CD11b+ DCs in atherosclerotic aorta also produce these 
inflammatory mediators.  





7.2.1 CD11b+ DCs produce TNF-α and iNOS  
 
We first assessed the ability of CD11b+ DCs to produce TNF-α and iNOS by 
intracellular flow cytometry. While we were able to detect TNF-α production 
by CD11b+ DCs (Figure 7.1A), we were unable to observe any iNOS 
production by CD11b+ DCs (data not shown). Interestingly, production of 
TNF-α was much higher in apoE-/- mice than in WT controls (Figure 7.1B).  
While we were unable to detect iNOS production by CD11b+ DCs using flow 
cytometry, we observed iNOS production by immunofluorescence. iNOS is 
mainly produced inside the plaque and in the shoulder regions when the 
plaque is advanced (Figure 7.2), suggesting that it may be involved in plaque 
stability. Importantly, serial sections showed colocalization of iNOS staining 
with I-A, CD11c and CD11b (Figure 7.2 A and B), indicating production by 
CD11b+ DCs. 
Often during inflammation, iNOS-derived NO is able to modify proteins 
through formation of peroxynitrite and this can be detected by its product, 
nitrotyrosine (Deeb et al., 2006). We speculated that CD11b+ DCs may be 
involved in nitration of proteins by virtue of its production of iNOS. 
Consistent with literature (Beckmann et al., 1994; Parastatidis et al., 2007), 
extensive nitration could be found in atherosclerotic plaques. Interestingly, the 
site of nitration coincided with the location of CD11b+ DCs (Figure 7.2C), 
suggesting that they may be involved in the modification of proteins in the 




plaque. One of the proteins that could be possibly modified is vascular 
endothelial cell growth factor C (VEGFC) (unpublished observations).



























Figure 7.1. CD11b+ DCs produced TNF-α in atherosclerotic aorta.  
(A) Monensin (1x) was added to aorta during digestion to block cytokine 
exocytosis. Thereafter, intracellular TNF-α staining was performed directly ex 
vivo on aortic cells without re-stimulation. Dot plots show intracellular TNF-α 
production by I-A+ CD11c+ CD11b+ DCs in apoE-/- and WT mice. (B) Bar 
graph comparing percentage of TNF-α-producing CD11b+ DCs. Data shown 
from 2 independent experiments, n = 2-3 mice per group. Student’s t-test: 

























Figure 7.2. CD11b+ DCs 
produce iNOS. 
(A) I-A+ CD11c+ DCs 
colocalized with production of 
iNOS in the plaque area (yellow 
arrows). L: lumen; I: intima; M: 
media; Adv: adventitia. Scale bar 
represents 50µm.  
 
A 




Figure 7.2. CD11b+ DCs 
produce iNOS. 
(B) Serial sections were 
stained with CD11b to verify 
DC population producing 
iNOS (yellow arrows). L: 
lumen; I: intima; M: media; 
Adv: adventitia. Scale bar 
represents 50µm.  
 
B 





Figure 7.2. CD11b+ DCs 
produce iNOS. 
(C) Serial sections showing 
nitrotyrosine staining with 
markers for DCs (yellow 
arrows).   L: lumen; I: intima; 
M: media; Adv: adventitia. 
Scale bar represents 50µm.  
 






To date, the function of CD11b+ DCs in atherosclerotic plaques remains 
unknown. Here, we show that CD11b+ DCs are major producers of TNF-α and 
iNOS.  Since both TNF-α and iNOS are pro-inflammatory in nature and are 
involved in the pathogenesis of atherosclerosis (Branen et al., 2004; Detmers 
et al., 2000; Kuhlencordt et al., 2001), this suggests that CD11b+ DCs are pro-
inflammatory in nature.   
Supporting this hypothesis, the site of protein nitration in atherosclerotic 
plaque, a process driven by iNOS, corresponded with the localization of 
CD11b+ DCs. Notably, protein nitration is known to alter and inactivate 
proteins that will always ultimately result in amplification of the inflammatory 
response (Smythe et al., 2003; Zou et al., 1997) in atherosclerotic lesion. 
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Chapter 8 – Discussion  
8.1 Expansion of aortic CD11b+ DCs in atherosclerosis is supported by 
monocytosis and GM-CSF 
 
Elucidating the origin and functional heterogeneity of aortic DC subsets 
during atherosclerosis is important for a better understanding of the 
pathogenesis of this deadly disease and for generation of suitable 
immunotherapy. Based on latest classification of non-lymphoid tissue DC 
subsets (Helft et al., 2010), we found that the aorta contains two non-lymphoid 
tissue DC subsets: CD103+ and CD11b+ DC subset which localized in 
atherosclerosis-susceptible regions of the aorta at steady state. Both DC 
subsets were replenished by hematopoietic cells and do not have the ability to 
self-renew like LCs (Helft et al., 2010; Merad et al., 2002). We went on to 
investigate these DC subsets in a mouse model of atherosclerosis, apoE-/-mice. 
We show for the first time that accumulation of aortic DCs in apoE-/- mice was 
due to an expansion of both CD11b+ and CD103+ DC subsets in 
atherosclerotic aortas.  
In terms of origin and function, the CD11b+ DC subset in non-lymphoid 
tissues even in the aorta is the least well-studied DC subset as many studies on 
non-lymphoid tissue DC subsets focused on the CD103+ DCs (Bachem et al., 
2012; Bogunovic et al., 2009; Choi et al., 2011; Ginhoux et al., 2009; Schulz 
et al., 2009). The non-lymphoid tissue CD11b+ DC subset is a heterogeneous 
population that is often described as macrophage-like (Denning et al., 2011), 
derived from circulating monocytes (Ginhoux et al., 2009; Varol et al., 2009) 
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and is found distributed between macrophage and cDC in a gene signature 
analysis (Miller et al., 2012). Hence, considering that this population was 
expanded in atherosclerosis implying a potential role for this DC subset in the 
disease, the CD11b+ DC subset warranted further investigation.  
The origin of the CD11b+ DC subset accumulating in atherosclerotic aortas is 
unknown. However, accumulation of the CD11b+ DC subset in other 
inflammatory conditions such as colitis (Rivollier et al., 2012), Cryptococcus 
neoformans fungal infection (Osterholzer et al., 2009) and diabetes (Yin et al., 
2012) indicated a monocytic origin for CD11b+ DCs. Furthermore, in the field 
of atherosclerosis, Ly6Chi monocytes and Ly6Clow monocytes have been 
shown to give rise to macrophages (Swirski et al., 2007) and CD11c+ DCs 
(Tacke et al., 2007), respectively.  
To determine the origin of this population, we made use of a monocyte-
derived cell marker, CD64 (Langlet et al., 2012; Plantinga et al., 2013; 
Tamoutounour et al., 2012). A higher proportion of the CD11b+ DC subset in 
apoE-/- mice was CD64+ compared to WT controls. This may imply that: 1) 
the CD11b+ DC subset is increasingly monocyte-derived under atherosclerotic 
conditions; 2) a growth factor in apoE-/- may be involved in this 
differentiation; 3) not all CD11b+ DCs are monocyte-derived, indicating other 
sources such as DC progenitors (Ginhoux et al., 2009); 4) CD11b+ DC in aorta 
seems also heterogeneous in term of origin alike other non-lymphoid CD11b+ 
DC subsets (Ginhoux et al., 2009).   
We subsequently confirmed that the CD11b+ subset arises from monocytes 
using adoptive transfer of monocytes. A proportion of adoptively transferred 
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WT monocytes into apoE-/- recipient mice were able to differentiate into 
CD11b+ DCs in the aorta. This was accompanied by a loss in detection of 
transferred monocytes in the blood circulation. Again, monocyte-derived 
CD11b+ DCs were CD64+, affirming the use of CD64 as a monocyte-derived 
cell marker (Langlet et al., 2012; Plantinga et al., 2013; Tamoutounour et al., 
2012).  
Since the CD11b+ DC subset is monocyte-derived, we hypothesized that the 
expansion of this population in atherosclerosis is related to an increase in 
circulating monocytes. It is well established that hypercholesterolemia induced 
monocytosis in apoE-/- mice (Combadiere et al., 2008; Swirski et al., 2007; 
Tacke et al., 2007). Of note, Gr-1low monocytes have been shown to express 
CD11c under hypercholesterolemic conditions in apoE-/- mice (Wu et al., 
2009). In this study, CD11c expression was found to be regulated by oxLDL 
and expression of CD11c played a role in monocyte adhesion to the 
endothelium, an important step in atherogenesis.    
We first verified that monocytosis occurred in our apoE-/- mice after 18 weeks 
of high fat diet feeding. To determine if monocytosis was a mechanism for the 
expansion of the CD11b+ DC subset in the aorta, we followed with a 
cholesterol-lowering drug treatment, Ezetimibe. Ezetimibe inhibits 
atherosclerosis development in apoE-/- mice (Davis et al., 2001; Kuhlencordt 
et al., 2009)  and monocyte migration in a rabbit model of atherosclerosis 
(Gomez-Garre et al., 2009). Expectedly, when hypercholesterolemia was 
decreased with Ezetimibe treatment in apoE-/- mice, monocytosis in the blood 
and aorta was simultaneously abrogated with CD11b+ DC accumulation in the 
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aorta. Thus, monocytosis likely supports CD11b+ DC accumulation in 
atherosclerotic aorta. 
Since an increasing proportion of the CD11b+ DC subset became monocyte-
derived under atherosclerotic conditions and a portion of adoptively 
transferred monocytes were able to differentiate into this population, this 
prompted us to examine if certain growth factors were involved in this 
process. Out of the known four DC growth factors (M-CSF, Flt3-L, GM-CSF 
and IL-34), we discovered that GM-CSF was the only factor that was highly 
expressed and locally produced in atherosclerotic aorta from apoE-/- mice. In 
addition, expression of GM-CSF was reduced together with CD11b+ DC 
expansion in Ezetimibe treated apoE-/- mice. 
The delicate balance of colony-stimulating factors particularly GM-CSF and 
M-CSF in atherosclerosis has been known to modify and polarize macrophage 
populations: GM-CSF-derived macrophages produce inflammatory cytokines 
whereas M-CSF-derived macrophages are anti-inflammatory (Brocheriou et 
al., 2011; Di Gregoli and Johnson, 2012). GM-CSF has also been known to 
induce DC-like macrophages and promote MHC class II expression whereas 
M-CSF inhibits MHC class II expression (Willman et al., 1989). Furthermore, 
GM-CSF has the ability to divert committed DCs to change phenotype (Zhan 
et al., 2012). Hence, the cytokine milieu in atherosclerosis can determine the 
phenotype of cells present in the plaque. GM-CSF has been shown to promote 
inflammatory DC formation in experimental autoimmune myocarditis 
(Blyszczuk et al., 2013) and to increase differentiation of monocytes into DCs 
(Miller et al., 2002; Zhan et al., 2011). Drawing from these observations, the 
Chapter 8 – Discussion  
148 
 
predominant expression of GM-CSF in apoE-/- mice suggested that the balance 
is likely tipped towards inflammatory DC formation in atherosclerotic plaques.  
We were then interested to know which cells were responsive to GM-CSF and 
the sources of GM-CSF in atherosclerotic plaques. We found that circulating 
monocytes express both the ligand binding (GMRα) and signaling subunit 
(CD131), with expression of CD131 being up-regulated in atherosclerotic 
conditions. In the aorta, we observed that only DCs expressed functional GM-
CSF receptors, with the CD11b+ DC subset expressing the highest levels of 
the signaling subunit (CD131) in apoE-/- mice.  
There are many potential cellular sources of GM-CSF in atherosclerotic 
plaques: T cells, monocytes, macrophages and even CD11b+ DCs. When we 
neutralized GM-CSF with an antibody, circulating monocytosis and CD11b+ 
DCs were decreased, demonstrating that GM-CSF contributed to CD11b+ DC 
accumulation in the atherosclerotic aorta. A couple of interesting observations 
emerged from this neutralization study. Firstly, although GM-CSF is not 
detectable in the circulation, neutralization of GM-CSF restored the ratio of 
monocyte subsets in the circulation and decreased monocytosis. GM-CSF may 
have a role in the release of monocytes from bone marrow (King et al., 2009) 
or prolonging the lifespan of monocytes by reducing apoptosis (Buschmann et 
al., 2001). Secondly, neutralization of GM-CSF reduced CD11b+ DCs but did 
not affect monocytes in the aorta. Also, circulating monocytes and CD11b+ 
DCs express functional GM-CSF receptors whereas aortic monocytes only 
express the signaling subunit CD131. Therefore, aortic monocytes may be 
incapable of responding to GM-CSF neutralization.    
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8.2 Pleiotrophic functions of GM-CSF in inflammation and 
autoimmunity 
 
GM-CSF has diverse functions in inflammation and autoimmunity. In an 
endothelial injury mouse model, the lack of GM-CSF delayed neointimal 
formation which is an early event in atherogenesis (Harris et al., 2009). 
Tumor-derived GM-CSF regulated the recruitment and development of Gr-1+ 
CD11b+ myeloid derived suppressor cells (MDSCs) in pancreatic cancer 
(Bayne et al., 2012) which can inhibit CD8+ T cell function (Bronte et al., 
1999) by preventing the maturation of these APCs. GM-CSF also has the 
ability to drive the release of Ly6Chi monocytes from the bone marrow which 
differentiated into central nervous system DCs and macrophages, thereby 
contributing to the pathogenesis of autoimmune demyelinating disease (King 
et al., 2009). 
On the other hand, GM-CSF is needed to confer protection from diabetes. 
Lack of GM-CSF promoted diabetes (Enzler et al., 2007) because GM-CSF is 
needed for the induction of IL-10 producing tolerogenic DCs that confer 
resistance to diabetes through maintenance of suppressive regulatory T cells 
(Gaudreau et al., 2007). The role of GM-CSF in immunosuppression is also 
evident in experimental autoimmune thyroiditis model (Vasu et al., 2003) and 
experimental autoimmune myasthenia gravis (Sheng et al., 2006).  
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8.3 How does GM-CSF exert its pleitrophic functions? 
 
GM-CSF can be both immunostimulatory and immunosuppressive. So how 
does it achieve this? Different concentrations of GM-CSF can produce 
different types of DCs. DCs cultured with low concentrations of GM-CSF are 
immature, resistant to maturation and tolerogenic in nature whereas those 
cultured with high concentrations of GM-CSF can still mature in response to 
stimuli and become immunocompetent DCs (Lutz et al., 2000). 
Biochemically, low concentrations of GM-CSF only promote cell survival 
whereas high concentrations of GM-CSF support both cell survival and 
proliferation (Hercus et al., 2009). The role of GM-CSF in inflammation is 
also dependent on stimulus. Lack of GM-CSF in thioglycollate-induced 
peritonitis has no consequence. However, in antigen-specific methylated BSA-
induced peritonitis, the lack of GM-CSF reduced peritonitis, inflammatory 
cells such as macrophages and inflammatory cytokines (Cook et al., 2004). 
In apoE-/- mice, we observed autocrine production of this cytokine by CD11b+ 
DCs and suspected that GM-CSF has a role to play in the survival of CD11b+ 
DC. To demonstrate this, we used BMDCs cultured with exogenous GM-CSF 
as a model as they resemble CD11b+ DCs phenotypically. We found that GM-
CSF prolonged BMDC survival and this may account for the CD11b+ DC 
accumulation in atherosclerotic aorta.  
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8.4 Function of CD11b+ DCs in atherosclerotic plaques 
 
GM-CSF derived DCs produced TNF-α and iNOS and are developmentally 
related to TipDCs (Xu et al., 2007). In colitis, monocyte-derived CD11b+ DCs 
are also pro-inflammatory, producing cytokines such as IL-12, IL-23, TNF-α 
and iNOS (Rivollier et al., 2012). In our study, we observed that both TNF-α 
and iNOS were produced by CD11b+ DCs in atherosclerotic plaques. TNF-α 
has been implicated in atherogenesis. The lack of this cytokine in apoE-/- mice 
reduced plaque size (Branen et al., 2004). This may be due to a decrease in 
adhesion molecules such as ICAM-1 and VCAM-1 and chemokine MCP-1, 
which are responsible for early recruitment of monocytes to atherosclerotic 
lesions (Ohta et al., 2005). Likewise, apoE-/- mice deficient in iNOS displayed 
reduced atherosclerotic lesion size but only at advanced stages (Detmers et al., 
2000; Kuhlencordt et al., 2001; Miyoshi et al., 2006). Deficiency in iNOS led 
to a direct reduction in aortic cholesterol (Detmers et al., 2000) whereas the 
other two studies showed a reduction in plasma lipid peroxides (Kuhlencordt 
et al., 2001; Miyoshi et al., 2006). Therefore, being able to produce both TNF-
α and iNOS, CD11b+ DCs are undeniably playing a pro-inflammatory and 
pro-atherogenic function in atherosclerosis.  
Moreover, nitric oxide (NO) produced by iNOS can lead to peroxynitrite 
formation which can lead to nitration of tyrosine residues. Protein tyrosine 
nitration was first detected in foam cells in human coronary arteries and 
hypothesized to contribute to the pathogenesis of atherosclerosis (Beckmann 
et al., 1994). Subsequently, massive protein nitration can be found in high-fat 
diet fed apoE-/- mice and this process was iNOS-dependent (Upmacis et al., 
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2007). One of the targets of protein tyrosine nitration in atherosclerotic 
plaques is prostaglandin H2 synthase. This enzyme is important for vascular 
homeostasis and nitration of its Tyr385 residue by iNOS led to its inactivation 
in apoE-/- mice (Deeb et al., 2006). In our study, we observed that CD11b+ 
DCs colocalized with sites of nitration in apoE-/- plaques, suggesting that 
iNOS produced by CD11b+ DCs may have resulted in nitration in 
atherosclerotic plaques. A proposed model of mechanisms governing the 
CD11b+ expansion and their functions is shown in Figure 8.1.




Figure 8.1. Proposed model for CD11b+ DC expansion and their function 
in atherosclerosis.  
Expansion of CD11b+ DCs is governed by monocytosis and GM-CSF. High 
concentrations of GM-CSF in atherosclerotic plaques could function in (1) 
recruitment of monocytes; (2) differentiation of monocytes into CD11b+ DCs; 
(3) survival and proliferation of CD11b+ DCs. CD11b+ DCs produce TNF-α 
and iNOS. Production of TNF-α upregulates ICAM-1, VCAM-1 and MCP-1 
for monocyte adherence to endothelium. iNOS could generate peroxynitrite 
(ONOO-) leading to nitration of proteins in atherosclerotic plaques. Art work 
adapted and modified from Servier Medical Art.  
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8.5 Limitations of our study 
8.5.1 ApoE: Functions beyond a lipid transport protein 
 
ApoE is not just involved in cholesterol metabolism. It can inhibit T cell 
proliferation in culture (Kelly et al., 1994). Lack of ApoE has been shown to 
enhance T cell stimulation and antigen presentation by an increase of co-
stimulatory molecules on macrophages (Tenger and Zhou, 2003). Moreover, 
ApoE is needed for clearance of apoptotic bodies. ApoE-/- macrophages 
demonstrated a reduced ability to ingest apoptotic bodies resulting in massive 
accumulation of apoptotic bodies. This in turn prompted production of TNF-α 
and increased recruitment of macrophages in response to increased dying 
macrophages (Grainger et al., 2004). As a consequence, there is increased 
number of Th1 and Th17 cells as well as an up-regulation of pro-inflammatory 
cytokines (Wei et al., 2013).  Considering the role of ApoE in antigen 
presentation and immune response, the accumulation of CD11b+ DCs in  
apoE-/- mice may be partially due to systemic inflammation in this mouse 
model. This may to some extent account for the more exaggerated 
accumulation of CD11b+ DCs in apoE-/- compared to Ldlr-/- mice.  
One limitation in using apoE-/- mice is transferring WT bone marrow into 
these mice results in reduction of hypercholesterolemia and atherosclerosis 
due to reconstitution of ApoE from WT cells (Boisvert et al., 1995; Llodra et 
al., 2004).  
 
Chapter 8 – Discussion  
155 
 
8.5.2 Relevance to human atherosclerosis 
 
ApoE deficiency in humans is rare and manifests itself in type III 
hyperlipoproteinemia where only 1 in 5,000 individuals is affected and clinical 
symptoms are only apparent at adulthood (Rall et al., 1989). In addition, apoE 
is polymorphic in humans having three different isoforms: ε2, ε3 and ε4 and 
this polymorphism is absent in mice (Plump and Breslow, 1995). Nonetheless, 
this limitation could be overcome because of the relative ease of genetic 
manipulation of mice. For example, mice expressing human apoE isoforms are 
able to recapitulate similar lipid profiles as humans (Pendse et al., 2009).  
Atherosclerosis in humans is also confounded by other factors such as 
diabetes, hypertension etc (Bentzon and Falk, 2010). Based on a single gene 
knockout, apoE-/- mice are probably best at modeling homozygous familial 
hypercholesterolemia in humans. However, the levels of hypercholesterolemia 
and similar predilection sites for atherosclerosis development in this mouse 
model in comparison to its human counterparts are redeeming qualities of this 
mouse model for its use in studying human atherosclerosis.  
As far as DC subsets in human atherosclerosis are concerned, four subtypes 
have been identified: classical myeloid DC (mDC) precursors (BDCA-1+), 
pDC precursors (BDCA-2+), mDCs (S100+ fascin+) and pDCs (CD123+). Both 
BDCA-1+ and BDCA-2+ DCs can be found in human atherosclerotic plaques 
with BDCA-1+ DCs being more predominant and both were shown to 
accumulate around neovessels (Van Vre et al., 2011). This observation 
coincided with a decrease of BDCA-1+ DCs in the circulation (Yilmaz et al., 
2006). mDCs can be found in normal aorta and increased across 
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atherosclerosis progression (Bobryshev and Lord, 1995a). Activated mDCs 
(CD83+) which accumulate in plaques are frequently found in contact with 
CD3+ T cells suggesting a role in T cell activation (Yilmaz et al., 2007).  
As the markers used in defining DC subsets in humans and mice markedly 
differ, it is difficult to relate studies from mouse models to human diseases. 
However, the equivalents of murine non-lymphoid tissue DC subsets to 
humans have been recently elucidated. Mouse CD103+ DC subset and CD11b+ 
CD24+ DC subset correspond in humans to CD141+ DC (Haniffa et al., 2012) 
and CD1c+ DC (BDCA-1+) (Schlitzer et al., 2013), respectively. It remains to 
be determined whether the CD11b+ DCs in murine atherosclerotic plaques are 
functionally equivalent to CD1c+ DCs or myeloid monocyte-derived CD14+ 
DCs in human atherosclerotic plaques.  
 
8.6 Developing therapeutic strategies for atherosclerosis 
8.6.1 Targeting against CD64 
 
CD64, which is Fc gamma receptor R I (FcγRI) is an activating receptor 
present on most myeloid cells such as monocytes, macrophages and DCs with 
a high affinity in binding immunoglobulins (van der Poel et al., 2011).  
Functions of CD64 include: 1) endocytosis of soluble IgG, 2) phagocytosis of 
immune complexes, 3) antibody-dependent cell-mediated cytotoxicity and 4) 
production of immune complex-induced inflammation (Barnes et al., 2002). A 
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lack of CD64 reduced the severity of cartilage damage in experimental 
antigen-induced arthritis (Ioan-Facsinay et al., 2002).  
The uptake of LDL-immune complexes by human macrophages was shown to 
be favored by CD64 which may contribute to foam cell formation (Lopes-
Virella et al., 1997). Moreover, deficiency of FcγR in apoE-/- mice displayed a 
reduction of atherosclerotic lesion size, macrophage and T cell content 
(Hernandez-Vargas et al., 2006). The immune mechanism behind this 
reduction of atherosclerotic size is attributed to decreased Th17 cell response 
and a shift towards regulatory T cell response (Ng et al., 2011). These findings 
imply that neutralization of Fcγ receptors may confer protection against 
atherosclerosis. Indeed, intravenous injection of immunoglobulin has been 
shown to attenuate atherosclerotic lesions in apoE-/- mice (Yuan et al., 2003) 
and induced anti-inflammatory effects resulting in improvement in chronic 
heart failure patients (Gullestad et al., 2001). Our finding that pro-
inflammatory CD11b+ DCs express higher CD64 expression under 
atherosclerotic conditions suggests that neutralizing CD64 may limit the 
expansion of CD11b+ DCs and atherosclerosis. 
 
8.6.2 Targeting against monocytosis 
 
Monocyte recruitment and accumulation in atherosclerotic plaques is 
proportional to the severity of the disease (Swirski et al., 2006). Our study also 
demonstrated that monocytosis contributes to the accumulation of CD11b+ 
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DCs in atherosclerosis. Therefore, targeting monocytosis should ameliorate 
atherosclerosis.  
Monocytes depend on chemokine receptors to migrate towards atherosclerotic 
plaques and inflammatory Gr-1hi monocytes depend on CCR2 (Combadiere et 
al., 2008; Tacke et al., 2007). Inflammatory Gr-1hi monocytes are detrimental 
to infarct healing (Nahrendorf et al., 2007). Nanoparticle-mediated silencing 
of CCR2 in myocardial infarction in apoE-/- mice displayed a reduction of 
monocytes and CD11b+ myeloid cells, resolving inflammation in infarcted 
hearts (Majmudar et al., 2013). 
Monocyte recruitment can also be blocked by a small molecule lecinoxoid, 
VB-201 in vitro (Feige et al., 2013). VB-201 was generated as an orally stable 
synthetic phospholipid analog, structurally similar to one of the oxidized 
phospholipid compound 1-pamitoyl-2-glutaryl phophatidylcholine (PGPC). 
Emerging data showed that not all oxidized phospholipids are pro-
inflammatory. In fact, some of them are anti-inflammatory in nature (Feige et 
al., 2010). In the study (Feige et al., 2013), VB-201 demonstrated a specific 
inhibition of monocyte chemotaxis by regulating downstream signaling of 
chemokine receptors in monocytes. Moreover, it inhibited monocyte migration 
in vivo in a model of sterile inflammation. When given to young apoE-/- mice 
for 8 weeks, VB-201 was able to attenuate atherosclerosis development and 
accumulation of CD68+ cells.  
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8.6.3 Targeting against GM-CSF 
 
We found that GM-CSF was over expressed in atherosclerotic lesions and this 
governs the accumulation of CD11b+ DCs. Although anti-GM-CSF therapy is 
still at its infant stage, its use in rheumatoid arthritis in Phase II clinical trials 
was efficacious and showed improved outcome for patients with mild adverse 
events (Nair et al., 2012). This is encouraging albeit more work still needs to 
be done to understand the consequences of GM-CSF over expression in 
atherosclerotic plaques.    
 
8.7 Future Work 
 
The role of GM-CSF in CD11b+ DCs is still not fully understood. GM-CSF 
can act at various levels: 1) recruitment of monocytes to atherosclerotic 
plaque; 2) differentiation of monocytes into CD11b+ DCs; 3) survival of 
CD11b+ DCs. In order to understand whether GM-CSF plays a part in 
recruitment of monocytes, we intend to isolate bone marrow monocytes and 
study their chemotaxis in vitro in transwell assay towards GM-CSF. This can 
also be shown in vivo with an adoptive transfer of monocytes from  
GM-CSFR-/- mice into apoE-/- recipients. If GM-CSF is not required for 
recruitment, the amount of monocytes arriving at atherosclerotic plaques 
should be similar as transferring WT monocytes into apoE-/- recipients. 
Examining the extent of CD11b+ DC accumulation in this study will also 
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allow us to conclude whether GM-CSF on monocytes is required for their 
differentiation into CD11b+ DCs in vivo during atherosclerosis. To evaluate if 
GM-CSF regulates the survival of CD11b+ DCs in vivo, we intend to measure 
the proportion of Annexin V+ CD11b+ DCs after neutralizing GM-CSF in 
apoE-/- recipients.  
GM-CSF is crucial to TH1 and TH17 responses in experimental autoimmune 
encephalomyelitis (Codarri et al., 2011; El-Behi et al., 2011). GM-CSF 
produced by TH17 cells is required for the maintenance of neuro-inflammation 
by recruitment of myeloid cells into the central nervous system (Codarri et al., 
2011).  TH17 cells are increased in apoE-/- mice in proportion to atherosclerotic 
plaque size (Gao et al., 2010; Smith et al., 2010). Neutralizing IL-17 reduced 
plaque burden, IL-6 and macrophage content (Smith et al., 2010). Genetic 
deletion of IL-17 in apoE-/- mice resulted in fewer dendritic cells and 
macrophages (Madhur et al., 2011). This was due to decreased monocyte 
migration to atherosclerotic aortas (Butcher et al., 2012). Since GM-CSF is 
produced by CD11b+ DCs in atherosclerotic plaques, they may be involved in 
the maintenance of the TH17 response whereby the atherosclerosis 
development is sustained and monocyte migration is promoted under the 
influence of IL-17. Hence, it will be interesting to explore this possibility by 
investigating whether TH17 responses are affected when GM-CSF is 
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Appendix 1 – Media and Buffers 
PBS (1x) 
8g NaCl, 0.2g KCl, 1.44g Na2HPO4, 0.24g KH2PO4 in 1 litre H2O, pH 7.4 
EasySepTM Buffer 
2% FBS, 1mM EDTA in PBS, pH7.4 
FACS Buffer 
1% normal mouse serum, 1% normal rat serum, 0.5% BSA, 2mM EDTA in 
PBS, pH 7.4 
BD Pharm LyseTM 
Pharm LyseTM concentrate (10x) diluted in distilled water to working 
concentration (1x), adjusted pH to 7.1 – 7.4  
Ammonium Chloride Solution 
0.9% ammonium chloride in distilled water 
RPMI-1640 Complete Medium  
RPMI (4500 mg/ml glucose) 450ml, FBS (10%) 50ml, Antibiotic-Antimycotic 
(1x) 5ml 
DAPI 
4’,6-Diamidino-2-phenylindole dihydrochloride reconstituted in distilled water 
and used at 1:20,000 dilution.  
IMDM Complete Medium 
 200 
 
IMDM 450ml, FBS (5%) 25ml, 200mM L-glutamine 5ml, G418 (1mg/ml) 
2% w/v Paraformaldehyde with 30% w/v Sucrose 




Appendix 2 – Antibodies for flow cytometry 
Antibody Company Clone 
CD11c PE-Cy7 eBioscience N418 
CD11b PerCP-Cy5.5 BD Pharmingen M1/70 
IA/IE FITC eBioscience M5/114.15.2 
CD24 eFluor 450 eBioscience M1/69 
CD64 APC BioLegend X54.5/7.1 
CD64 PE BioLegend X54.5/7.1 
IA Alexa Fluor 700 eBioscience M5/114.15.2 
CD45 APC-Cy7 BD Pharmingen 30-F11 
Gr-1 PE BD Pharmingen RB6-8C5 
Gr-1 APC BD Pharmingen RB6-8C5 
CD103 PE eBioscience 2E7 
Ly6G FITC eBioscience RB6-8C5 
Sirp α FITC BD Pharmingen P84 
F4/80 FITC AbD Serotec C1:A3-1 
c-kit PE-Cy7 eBioscience 2B8 
Biotinylated Flt3 eBioscience A2F10 




CD115 biotin eBioscience AFS98 
Streptavidin-PB Invitrogen NA 
CD115 PE eBioscience AFS98 
CD11c PB BioLegencd N418 
Biotinylated CD45.1  BD Pharmingen A20 
CD45.1 PerCP-Cy5.5 eBioscience A20 
TER119 APC eBioscience TER-119 
CD19 APC eBioscience eBio1D3 
CD3 APC eBioscience 145-2C11 
B220 APC eBioscience RA3-6B2 
 202 
 
NK1.1 APC eBioscience PK136 
Sca-1 APC eBioscience D7 
CD11b APC-Cy7 eBioscience M1/70 
GMRα APC R&D Systems 698423 
CD131 PE BD Pharmingen JORO 50 
Rat IgG2a APC eBioscience NA 
Rat IgG1 PE eBioscience NA 
Rat IgG1 eFluor 450 eBioscience NA 
TNF-α eFluor 450 eBioscience MP6-XT22 
GM-CSF PE eBioscience MP1-22E9 
iNOS (Rabbit anti-
mouse) 
BD Pharmingen NA 
Anti-Rabbit APC Invitrogen NA 




Appendix 3 – Antibodies for immunofluorescence 
Antibody Company Clone 
 iNOS (Rabbit) Calbiochem NA 
GM-CSF (Rabbit) Santa Cruz FL-144 
Nitrotyrosine (Rabbit) Millipore NA 
I-A/I-E eBioscience M5/114.15.2 
Armenian Hamster IgG BD Pharmingen H94/8 
CD11b eBioscience M1/70 
Rabbit IgG Jackson Immuno NA 
CD11c eBioscience HL-3 
CD3ε eBioscience 145-2C11 
Anti-Armenian Hamster 
HRP 
Jackson Immuno NA 
Anti-Rat HRP Jackson Immuno NA 
Anti-Rat AF647, Cy2 Jackson Immuno NA 
Anti-Armeniam 
Hamster IgG Dylight 
647 
Jackson Immuno NA 




Appendix 4 – Primers for qPCR 
Target gene Primer sequence (5’ → 3’) 
Flt3 L Forward GGAGCCCAAATTCCTCCCTGTTGC 
Flt3 L Reverse GGAGCCTCTTCCTAGCCCAGCG 
GM-CSF Forward GCCTGAAGATATTCGAGCAGGGTCTAC 
GM-CSF Reverse GCATTCAAAGGGGATATCAGTCAGAAAGGTT 
M-CSF Forward TCATGAGCAGGAGTATTGCCAA 
M-CSF Reverse GGCAATCTGGCATGAAGTCTC 
IL-34 Forward GGGTCATGGAACTGCTGTACT 
 
IL-34 Reverse ATCAAGGACCCCGGACTG 
 
GM-CSF Receptor β2 
 
GGACGACTGACTGGGTGATG 
GM-CSF Receptor β2 
 
AACACGGCCAAAGTGGAGAG 
GM-CSF Receptor α 
 
CCTGCTCTTCTCCACGCTAC 
GM-CSF Receptor α 
 
GTCGAAGGTCAGGTTGAGGG 
GM-CSF Receptor β 
 
TAGGAAGAGCCTGCAACTCAC 
GM-CSF Receptor β 
 
ACTGCATCCTTTGTGGCTCTG 
IL-3 Receptor α 
 
AGATGATGATGGCGACCACG 
IL-3 Receptor α 
 
GCACATCACGCCAGAACATC 
IL-5 Receptor α 
 
GCCATTGACCAAGTGAATCCTC 
IL-5 Receptor α 
 
GAGCTCACAGCTGCTCTCAC 
IL-3 Forward TCTGCGAATGACTCTGCGCTGC 
IL-3 Reverse GAGACGGAGCCAGATGCGGG 
GAPDH Forward GACGGCCGCATCTTCTTGTG 
 
GAPDH Reverse CTTCCCATTCTCGGCCTTGACTGT 
 
 
 
 
 
